

Mutations make pandemics worse or better: modeling SARS-CoV-2 variants and imperfect vaccination

Sarita Bugalia¹, Jai Prakash Tripathi¹, Hao Wang²

¹ Department of Mathematics, Central University of Rajasthan,
Bandar Sindri, Kishangarh-305817, Ajmer, Rajasthan, India

² Department of Mathematical and Statistical Sciences,
University of Alberta, Edmonton AB T6G 2G1, Canada

Abstract

COVID-19 is a respiratory disease triggered by an RNA virus inclined to mutations. Since December 2020, variants of COVID-19 (especially Delta and Omicron) continuously appeared with different characteristics that influenced death and transmissibility emerged around the world. To address the novel dynamics of the disease, we propose and analyze a dynamical model of two strains, namely native and mutant, transmission dynamics with mutation and imperfect vaccination. It is also assumed that the recuperated individuals from the native strain can be infected with mutant strain through the direct contact with individual or contaminated surfaces or aerosols. We compute the basic reproduction number for each strain independently and take the maximum for R_0 . We prove the nonexistence of backward bifurcation using the center manifold theory, and global stability of disease-free equilibrium when the basic reproduction number $R_0 < 1$, that is, vaccine is effective to eliminate the native and mutant strains even if it cannot provide full protection. Hopf bifurcation appears when the endemic equilibrium loses its stability. An intermediate mutation rate ν_1 leads to oscillations. When ν_1 increases over a threshold, the system regains its stability and exhibits an interesting dynamics called endemic bubble. An analytical expression for vaccine-induced herd immunity is derived. The epidemiological implication of the herd immunity threshold is that the disease can be effectively eradicated if the minimum herd immunity threshold is attained in the community. Furthermore, the model is parameterized using the Indian data of the cumulative number of confirmed cases and deaths of COVID-19 from March 1 to September 27 in 2021, using MCMC method. The cumulative cases and deaths can be reduced by increasing the vaccine efficacies to both native and mutant strains. We observe that by considering the vaccine efficacy to native strain as 90%, the cumulative cases and deaths would be reduced by 3.27% and 5.2%, respectively; and by considering the vaccine efficacy to mutant strain as 90%, the cumulative cases and deaths would be reduced by 0.9% and 2.5%, respectively. Our study demonstrates that the COVID-19 pandemic may be worse due to the occurrence of oscillations for certain mutation rates (i.e., outbreaks will occur repeatedly) but better due to stability at a lower infection level with a larger mutation rate. We perform sensitivity analysis using the Latin Hypercube Sampling (LHS) methodology and partial rank correlation coefficients (PRCCs) to illustrate the impact of parameters on the basic reproduction number, the number of cumulative cases, and the number of deaths, which ultimately sheds light on disease mitigation.

Keywords: COVID-19; Endemic bubble; Mutation; Imperfect vaccination; MCMC; Two strain dynamics; Hopf bifurcation; Transcritical bifurcation; Sensitivity analysis.

1 Introduction

Contagious diseases are one of the foremost reasons for demise worldwide. The spread of contagious diseases dangerously affects the growth of countries and the evolution of a population. Though modern scientific medicine has made rapid advancements, the diseases have not been completely eradicated. Diseases have obtained new versions due to the genetic variations of

pathogens triggered via mutations. Many pathogens are characterized by more than one variant [58, 65]. Virus or pathogens mutations are general in contagious diseases such as HBV [65], Influenza [58], and HIV [22]. Multi-strain of 1918 avian influenza virus with the mutation have been recognized by Iwami et al. [35]. The existence of different variants of a pathogen is mainly due to resist immune attacks of the host or induced by treatment with antiviral drugs or antibodies [22]. Ultimately, they confirm the persistence of disease in a host. Sansonetti and Arondel [64] have revealed that mutant strains can be associated with higher virulence to disease than the native strains, and those people diseased with mutant strains have a higher death rate in the contagious diseases such as plague, influenza A, etc. Thus, one of the major challenges in stopping the spread of infectious diseases is to treat with the genetic variations of pathogens [44, 52, 59]. Mathematical models are helpful to describe and understand the dynamics of different strains under mutation. Various epidemic models with multi-strain contacts and mutation have been proposed in recent years from different aspects [12, 43, 44, 51]. Liu et al. [44] proposed a mathematical model for Influenza with virus mutation and analyzed the model in the sense of permanence of the disease. Cai et al. [12] proposed a two-strain model with vaccination. The authors studied the existence and stability of the equilibria as well as the existence of Hopf bifurcation from endemic equilibria. Li et al. [43] proposed a two-strain SIR model with infection age and mutation. The authors analyzed the stability of equilibria and Hopf bifurcation. Moreover, epidemiological investigations have exposed that the phenomenon of mutations leads to further resistant viruses giving the emergence of many new dangerous epidemics or even new serious pandemics.

Since December 2019, a novel coronavirus (identified to produce a respiratory disease acknowledged as COVID-19) has spread broadly and rapidly and has since oppressed a significant proportion of the population worldwide. The World Health Organization (WHO) has detected the spread of COVID-19 as a pandemic, and as of December 4, 2021, over 263 million peoples were diseased, and about 5.2 million died of the virus. The SARS-CoV-2 virus triggered by severe acute respiratory syndrome is also mutating. Lately, numerous variants of the SARS-CoV-2 virus have been identified. These variants are described according to the number and types of mutations [39, 42]. Since the start of the COVID-19 pandemic, the SARS-CoV-2 coronavirus that initiated COVID-19 has mutated, rising in different variants of the virus. Numerous SARS-CoV-2 variants have developed worldwide, and the presence of different variants depends on several factors. One of these is called the delta variant, which was first identified in India [17]. Different variants have appeared in Brazil, England, California, and other countries. More transmittable variants such as beta, which first emerged in South Africa, may have improved the ability to re-infect individuals who have recuperated from previous versions of the virus and also be somewhat resistant to some of the coronavirus vaccines in development [36]. These new variants might have distinct features that can influence the death rate and transmissibility [25, 39, 42]. From October 2020, the number of infected cases of SARS-CoV-2 and related deaths augmented drastically in England. It has been discovered that the new SARS-CoV-2 variant VOC-202012/01 was widespread, and its proportion amplified throughout the latest months in England [10, 62]. The mutations of viruses are frequent, and, as an outcome, SARS-CoV-2 can develop mutations with immunological resistance and fitness advantages [39]. It is anticipated that further mutations will occur worldwide and probably even more after worldwide vaccination due to mutation force [63]. Therefore, analyzing the effect of new strains of the SARS-CoV-2 virus is supremely significant. In the literature, a few authors proposed multi-variant mathematical models for COVID-19 [6, 25, 38]. Gonzalez-Parra et al. [25] studied the effect of a new, more infectious SARS-CoV-2 variant (VOC-202012/01 of lineage B.1.1.7) on hospitalizations, prevalence, and deaths associated with the SARS-CoV-2 virus. Khyar et al. [38] proposed a multi-strain SEIR model with general incident rate and studied the global dynamics of the model. The authors also discussed the quarantine strategy for controlling the

disease spread and fit the model to the Moroccan clinical data of COVID-19. Arruda et al. [6] proposed a model for COVID-19 and studied the optimal control of multi-strain epidemics.

Vaccination has been an effective strategy in battling the spread of contagious diseases, e.g., measles, influenza, and pertussis. In history, the elimination of smallpox has been counted as the most notable victory of vaccination ever recorded [72]. Several authors in multiple papers have investigated the role of vaccination [2, 5, 12–14, 27, 47, 51, 66]. Under vaccination concern, certain mutant strains will finally have the competitive benefits amongst their contacts [66]. The impact of vaccination on the growth of strain contacts in multi-strain viruses has also been analyzed in many papers [28, 53, 54, 60, 61]. With the latest development of anti-COVID vaccines, numerous models have been proposed to provide insight into the impact of vaccination of a certain fraction of the populace on the dynamics of the COVID-19 pandemic. For instance, Fudolig et al. [24] proposed a multi-strain model with vaccination for COVID-19 and studied the local stability of equilibria. Furthermore, there is some evidence of COVID-19's vaccine efficacy in Australia that mRNA vaccine has over 90 % efficacy against COVID-19 infection, ChAdOx1 nCoV-19 has efficacy of 62% against symptomatic infection in the intended two-dose schedule, BNT162b2 mRNA vaccine, which has 95% efficacy against symptomatic infection [48]. Also, the Pfizer-BioNTech BNT162b2 mRNA vaccine has an efficacy over 95%, Johnson & Johnson [J&J] Ad26 has an efficacy over 67%, the AstraZeneca–Oxford ChAdOx1 nCov-19 vaccine has an efficacy over 67%, and the Gamaleya GamCovidVac [Sputnik V] vaccine has the efficacy over 90% [57]. According to the Ministry of Health and Family Welfare, Government of India, the Indian vaccine also has vaccine efficacy over 70-90% [55].

To determine effectual countermeasures, it is significant to develop mathematical models that support us in predicting and understanding the spread of COVID-19 and providing strategies on what could be implemented to limit its spread. Mathematical modeling in epidemiology provides a progressively greater room to public health research. This research discipline participates to sufficiently comprehend the studied epidemiological phenomenon and capture the distinct issues that can give rise to a terrible epidemic or even an alarming pandemic worldwide. The classical susceptible-infected-recovered (SIR) epidemic model was first proposed by Kermack et al. [37]. To obtain a sharper understanding of various vaccination strategies and their impacts on the number of infected individuals, Kermack-McKendrick type models have grabbed a vital role. This type of model has been benefited to comprehend vaccination dynamics on various diseases [2]. It is essential to emphasize that nowadays, Kermack-McKendrick kind mathematical models have helped explain COVID-19 epidemics properties worldwide. These models have been utilized to estimate the basic reproductive number associated with the disease and various parameters engaged in its spread. Additional use of this type of models has been focused on proposing and assessing the impact of different control measures categorized as NPIs. For example, the authors in papers [7–9] proposed mathematical models for COVID-19 and analyzed the impact of NPIs on the disease dynamics. It is of paramount significance to develop mathematical models that can perfectly forecast the spread of COVID-19 so that the disease can be controlled and restrictions can be securely relaxed. However, the infection incubation period may occupy a long time interval in some cases. An incubated person is not yet infectious in this time interval and remains latent. Therefore, another compartment of exposed individuals should be included in SIR, and the new model will have SEIR abbreviation [32].

Inspired by the evidence mentioned above about imperfect vaccine and mutation of the virus, in this paper we utilize an SEIR-type mathematical model to comprehend the dynamics of disease spread on the human populace under imperfect vaccination and two variants of the virus. The general methodology and mathematical model can be inferred to enhance the number of parameters and differential equations. We incorporate the vaccination compartment to the two-strain model to examine the effectiveness of the anti-COVID-19 vaccination, which is currently being employed in many countries to help battle the intense pandemic situation. It

is supposed that the spread of a virus can mutate in the host to make a second, co-circulating, mutant strain. After some period of infection, the original strain, referred to as native strain, is converted to a mutant strain, such that a proportion of the people infected by the original strain are also carrying mutant strain, thus we consider mutation in our proposed epidemic model. We intend to study the dynamical behavior of the strains' contacts under the vaccination scheme and investigate the impact of parameters (vaccination proportion, mutation rate, etc.) to demonstrate how they influence disease transmission. We also assume that recovered individuals from native strain have 100% immunity against native strain but can be infected by mutant strain. The objectives of the present study are the following: (i) Construction of an epidemic model that will describe the dynamics of mutant strain under imperfect vaccination. (ii) Investigation of the impact of an imperfect vaccine on the dynamics of the model. (iii) Investigation of different bifurcations with respect to variation of various parameters. (iv) Application of the proposed model to the data of COVID-19 in India. (v) Observation of the COVID-19 dynamics with respect to the key parameter related to the mutation.

The remaining paper is organized as follows. Section 2 describes the proposed model with imperfect vaccine and mutation. Section 3 discusses the non-negativity and boundedness of the solutions of the proposed system. Section 4 represents the dynamical analysis of the proposed system including the basic reproduction number, existence, and stability of possible equilibria, transcritical bifurcation, and Hopf bifurcation. Section 5 describes the implications of disease control, and we obtained explicit expression of vaccine-induced herd immunity. Numerical evaluations have been presented in Section 6. Cumulative cases and cumulative mortality data for COVID-19 pandemic in India have been used to parametrize the model, and the impact of different parameters on the cumulative cases and deaths have been shown in Section 7. Sensitivity analysis of the parameters with respect to the basic reproduction number, cumulative cases, and cumulative deaths has been performed in Section 8. The paper ends with a thorough discussion in Section 9.

2 Model formulation

We introduce a homogeneous two-strain model with imperfect vaccination. The system starts with a population exposed to both the native (original) and mutant (variant of original) strains of the virus. Some previous studies [19, 25] revealed that the variant is more transmissible and severe than the original strain, and antibody neutralization is reduced in COVID-19 patients and vaccine recipients in various countries, including the US. Nature news has reported that the mutant strain is spreading quickly in India and has become the dominant strain [56]. A mutation is accounted for in epidemic models through a term that transfers individuals infected with one of the strains into individuals infected with the other [12, 44, 50]. We assume that vaccination is applied only to healthy individuals, so only susceptible individuals get vaccinated. Further, we also assume that the vaccine is imperfect, that is, the vaccinated individuals can become infected with both native and mutant strains of the virus. That happens at reduced transmission rates $\delta_1\beta_1$ and $\delta_2\beta_2$, where $0 \leq \delta_1 \leq 1, 0 \leq \delta_2 \leq 1$ are the reduction coefficients of native and mutant strains, respectively. If $\delta_1 = 0$, then vaccinated individuals will not get infected with native strain, i.e., the vaccine is perfect for native strain, and $\delta_1 = 1$ means vaccinated individuals get infected just like susceptible individuals, i.e., vaccine plays no protective role to native strain. Here $1 - \delta_1$ describes the vaccine efficacy to native strain. A similar scenario applies to the mutant strain, and $1 - \delta_2$ describes the vaccine efficacy to the mutant strain. Some vaccinated individuals can go back to susceptible individuals due to partial immunity. There are some shreds of evidence that there is a chance of a second COVID-19 infection after being diagnosed with first, from which recovered [18, 31, 67]. Therefore, we assume that the recovered individuals of native strain can also become infected via mutant strain of the virus at a reduced rate $\delta_3\beta_2$.

The model is composed of a system of differential equations that has eight compartments: susceptible compartment S — individuals in this compartments are healthy but can be infected by both the native and mutant strains of the virus; vaccinated compartment V — individuals that applied to vaccination, these individuals can also become infected by both the native and mutant strains of the virus but at lower rates; exposed compartment E_1 — individuals that are exposed to a native strain of virus; exposed compartment E_2 — individuals that are exposed to a mutant strain of virus; infected compartment I_1 — individuals that are infected to a native strain of virus; infected compartment I_2 — Individuals that are infected to a mutant strain of virus; recovered compartment R_1 — individuals that were infected to native strain and are now immune to the native strain but not immune to the mutant strain; recovered compartment R_2 — individuals infected with mutant strain are now immune to both native and mutant strains and do not interact with the remaining compartments. The biological interpretations of the parameters involved in the model are given in Table 1. The schematic diagram of the model is given in Figure 1. The total population size is $N(t) = S(t) + V(t) + E_1(t) + E_2(t) + I_1(t) + I_2(t) + R_1(t) + R_2(t)$.

Parameters	Biological interpretations
Λ	The recruitment rate at which new individuals enter in the susceptible population
β_1	Infection rate of the native strain
β_2	Infection rate of the mutant strain
p	Per capita vaccination rate of susceptible individuals
$1/\mu$	Average life expectancy of the individuals of all compartments
$1 - \delta_1$	Efficacy of vaccine to native strain
$1 - \delta_2$	Efficacy of vaccine to mutant strain
γ	Per capita rate of lost of immunity of vaccinated individuals
a_1	Per capita rate at which the exposed individuals of native strain become infectious
a_2	Per capita rate at which the exposed individuals of mutant strain become infectious
α_1	Per capita recovery rate of native strain
α_2	Per capita recovery rate of mutant strain
d_1	Per capita death rate due to native strain
d_2	Per capita death rate due to mutant strain
δ_3	Reduction coefficient of infection after recovery
ν_1	Per capita mutation rate of native strain

Table 1: Biological interpretations of parameters.

Based on the parameters given in Table 1 and schematic diagram 1, the dynamics of the




Figure 1: Schematic diagram of system (1).

disease transmission can be governed by the following system of ordinary differential equations:

$$\begin{aligned}
 \frac{dS}{dt} &= \Lambda - \beta_1 I_1 S - \beta_2 I_2 S - (\mu + p)S + \gamma V, \\
 \frac{dV}{dt} &= pS - \delta_1 \beta_1 I_1 V - \delta_2 \beta_2 I_2 V - (\mu + \gamma)V, \\
 \frac{dE_1}{dt} &= \beta_1 (S + \delta_1 V) I_1 - (a_1 + \mu)E_1, \\
 \frac{dE_2}{dt} &= \beta_2 (S + \delta_2 V + \delta_3 R_1) I_2 - (a_2 + \mu)E_2, \\
 \frac{dI_1}{dt} &= a_1 E_1 - (\alpha_1 + \mu + d_1 + \nu_1)I_1, \\
 \frac{dI_2}{dt} &= a_2 E_2 - (\alpha_2 + \mu + d_2)I_2 + \nu_1 I_1, \\
 \frac{dR_1}{dt} &= \alpha_1 I_1 - \delta_3 \beta_2 I_2 R_1 - \mu R_1, \\
 \frac{dR_2}{dt} &= \alpha_2 I_2 - \mu R_2,
 \end{aligned} \tag{1}$$

with the initial conditions: $S(0) > 0, V(0) \geq 0, E_1(0) \geq 0, E_2(0) \geq 0, I_1(0) \geq 0, I_2(0) \geq 0, R_1(0) \geq 0, R_2(0) \geq 0$.

3 Well-posedness

This section summarizes the positivity and boundedness of solutions of system (1). Positivity is significant for biologically feasible solutions of the system while boundedness infers that

solutions are finite. System (1) is given by the following bounded planes:

$$\begin{aligned}
\left. \frac{dS}{dt} \right|_{S=0, V \neq 0, E_1 \neq 0, E_2 \neq 0, I_1 \neq 0, I_2 \neq 0, R_1 \neq 0, R_2 \neq 0} &= \Lambda + \gamma V > 0, \\
\left. \frac{dV}{dt} \right|_{S \neq 0, V=0, E_1 \neq 0, E_2 \neq 0, I_1 \neq 0, I_2 \neq 0, R_1 \neq 0, R_2 \neq 0} &= pS \geq 0, \\
\left. \frac{dE_1}{dt} \right|_{S \neq 0, V \neq 0, E_1=0, E_2 \neq 0, I_1 \neq 0, I_2 \neq 0, R_1 \neq 0, R_2 \neq 0} &= \beta_1(S + \delta_1 V)I_1 \geq 0, \\
\left. \frac{dE_2}{dt} \right|_{S \neq 0, V \neq 0, E_1 \neq 0, E_2=0, I_1 \neq 0, I_2 \neq 0, R_1 \neq 0, R_2 \neq 0} &= \beta_2(S + \delta_2 V)I_2 + \delta_3 \beta_2 I_2 R_1 \geq 0, \\
\left. \frac{dI_1}{dt} \right|_{S \neq 0, V \neq 0, E_1 \neq 0, E_2 \neq 0, I_1=0, I_2 \neq 0, R_1 \neq 0, R_2 \neq 0} &= a_1 E_1 \geq 0, \\
\left. \frac{dI_2}{dt} \right|_{S \neq 0, V \neq 0, E_1 \neq 0, E_2 \neq 0, I_1 \neq 0, I_2=0, R_1 \neq 0, R_2 \neq 0} &= a_2 E_2 + \nu_1 I_1 \geq 0, \\
\left. \frac{dR_1}{dt} \right|_{S \neq 0, V \neq 0, E_1 \neq 0, E_2 \neq 0, I_1 \neq 0, I_2 \neq 0, R_1=0, R_2 \neq 0} &= \alpha_1 I_1 \geq 0, \\
\left. \frac{dR_2}{dt} \right|_{S \neq 0, V \neq 0, E_1 \neq 0, E_2 \neq 0, I_1 \neq 0, I_2 \neq 0, R_1 \neq 0, R_2=0} &= \alpha_2 I_2 \geq 0.
\end{aligned}$$

Note that on each of the bounding planes of the non-negative cone of \mathbb{R}_+^8 , all rates in the system (1) are non-negative. Thus, if we initiate this in the interior of this cone, we shall always remain in this cone as the direction of the vector field is inward on all the bounding planes. Therefore, the non-negativity of all solutions is guaranteed if we start from a non-negative initial point. Furthermore, system (1) also states that the population N follows the below differential equation:

$$\frac{dN}{dt} = \Lambda - \mu N - d_1 I_1 - d_2 I_2, \quad (2)$$

which gives

$$\Lambda - (\mu + d_1 + d_2)N \leq \frac{dN}{dt} \leq \Lambda - \mu N.$$

Now integrating the above inequality and using initial conditions, we obtain

$$\frac{\Lambda}{\mu + d_1 + d_2} + \left(N(0) - \frac{\Lambda}{\mu + d_1 + d_2} \right) e^{-(\mu + d_1 + d_2)t} \leq N(t) \leq \frac{\Lambda}{\mu} + \left(N(0) - \frac{\Lambda}{\mu} \right) e^{-\mu t},$$

Considering $t \rightarrow +\infty$, we obtain

$$\frac{\Lambda}{\mu + d_1 + d_2} \leq \liminf_{t \rightarrow +\infty} N(t) \leq \limsup_{t \rightarrow +\infty} N(t) \leq \frac{\Lambda}{\mu}.$$

Hence, the feasible region for the system (1) is

$$\Delta = \left\{ (S, V, E_1, E_2, I_1, I_2, R_1, R_2) \in \mathbb{R}_+^8 : 0 < S + V + E_1 + E_2 + I_1 + I_2 + R_1 + R_2 \leq \frac{\Lambda}{\mu} \subset \mathbb{R}_+^8 \right\}.$$

From the above analysis, we conclude the following consequence:

Theorem 3.1. *The region Δ is positively invariant and attracting.*

Therefore, the system (1) is well-posed and epidemiologically feasible since all variables

remain nonnegative for all $t \geq 0$. Further, since the equations of system (1) are continuous and have continuous partial derivatives, then they satisfy the Lipschitz condition. Additionally, from Theorem 3.1, system (1) is uniformly bounded. Hence, the solution of the system (1) exists and is unique.

4 Rigorous analysis

This section is devoted to investigating the dynamical behaviors of system (1) including the computation of the basic reproduction number, the existence of possible equilibria and their stability, and possible bifurcations.

4.1 Disease free equilibrium (DFE) and basic reproduction number

The disease free equilibrium (DFE) can be obtained by setting all infected variables (E_1, E_2, I_1, I_2) equal to zero while all non-infected variables (S, V, R_1, R_2) are non-zero. The DFE of system (1) is given by

$$D^0 = (S^0, V^0, E_1^0, E_2^0, I_1^0, I_2^0, R_1^0, R_2^0) = \left(\frac{\Lambda(\mu + \gamma)}{\mu(\mu + \gamma + p)}, \frac{\Lambda p}{\mu(\mu + \gamma + p)}, 0, 0, 0, 0, 0, 0 \right). \quad (3)$$

To obtain the basic reproduction number, we use the next generation method [20, 68]. By considering $x = (E_1, E_2, I_1, I_2)^T$, we have

$$x' = f(x) - v(x), \quad (4)$$

where

$$f = \begin{pmatrix} \beta_1(S + \delta_1 V)I_1 \\ \beta_2(S + \delta_2 V)I_2 + \delta_3 \beta_2 I_2 R_1 \\ 0 \\ 0 \end{pmatrix}, \quad v = \begin{pmatrix} (a_1 + \mu)E_1 \\ (a_2 + \mu)E_2 \\ (\alpha_1 + \mu + d_1 + \nu_1)I_1 - a_1 E_1 \\ (\alpha_2 + \mu + d_2)I_2 - \nu_1 I_1 - a_2 E_2 \end{pmatrix}.$$

The Jacobian of $f(x)$ and $v(x)$ at D^0 are

$$F = Df(D^0) = \begin{pmatrix} 0 & 0 & \beta_1(S^0 + \delta_1 V^0) & 0 \\ 0 & 0 & 0 & \beta_2(S^0 + \delta_2 V^0) \\ 0 & 0 & 0 & 0 \\ 0 & 0 & 0 & 0 \end{pmatrix},$$

and

$$V = Dv(D^0) = \begin{pmatrix} (a_1 + \mu) & 0 & 0 & 0 \\ 0 & (a_2 + \mu) & 0 & 0 \\ -a_1 & 0 & (\alpha_1 + \mu + d_1 + \nu_1) & 0 \\ 0 & -a_2 & -\nu_1 & (\alpha_2 + \mu + d_2) \end{pmatrix},$$

respectively. Hence, the basic reproduction number for system (1) is the dominant eigenvalue or spectral radius of the next generation matrix FV^{-1} which is given by the following expression:

$$R_0 = \rho(FV^{-1}) = \max \{R_1, R_2\}, \quad (5)$$

where

$$\begin{aligned}
R_1 &= \frac{\beta_1 a_1 (S^0 + \delta_1 V^0)}{(\mu + a_1)(\mu + d_1 + \alpha_1 + \nu_1)} \\
&= \frac{\Lambda \beta_1 a_1 (\gamma + \mu + p \delta_1)}{\mu(\mu + a_1)(\mu + d_1 + \alpha_1 + \nu_1)(p + \gamma + \mu)}, \\
R_2 &= \frac{\beta_2 a_2 (S^0 + \delta_2 V^0)}{(\mu + a_2)(\mu + d_2 + \alpha_2)} \\
&= \frac{\Lambda \beta_2 a_2 (\gamma + \mu + p \delta_2)}{\mu(\mu + a_2)(\mu + d_2 + \alpha_2)(p + \gamma + \mu)}.
\end{aligned}$$

Here $R_1(R_2)$ represents the average number of secondary infection cases generated by a single infectious individuals of the native (mutant) strain of the virus, called the basic reproduction number of the native (mutant) strain.

4.1.1 Interpretation of the basic reproduction number

As stated above, the basic reproduction number R_0 is the maximum of the two basic reproduction numbers, R_1 and R_2 . The basic reproduction number R_1 is given by the product of the infection rate of the susceptible (unvaccinated) and vaccinated individuals by native strain infectious individuals (near the disease-free equilibrium), $[\beta_1(S^0 + \delta_1 V^0)]$, the proportion of the exposed individuals to the native strain that survived in the exposed class (E_1) and moved to infected compartment (I_1) $[\frac{a_1}{\mu + a_1}]$, and the average time duration in the infectious class (I_1) $[\frac{1}{\mu + d_1 + \alpha_1 + \nu_1}]$. The basic reproduction number R_2 is given by the product of the infection rate of the susceptible (unvaccinated) and vaccinated individuals by the mutant strain infectious individuals (near the disease-free equilibrium), $[\beta_2(S^0 + \delta_1 V^0)]$, the proportion of the exposed individuals to the mutant strain that survived in the exposed class (E_2) and moved to infected compartment (I_2) $[\frac{a_2}{\mu + a_2}]$, and the average time duration in the infectious class (I_2) $[\frac{1}{\mu + d_2 + \alpha_2}]$.

Remark 4.1. If $\delta_1 = 0, \delta_2 = 0$, then vaccine is perfectly effective to both native and mutant strains and if $p = 0$ then the system reduces without vaccination. For this case, the basic reproduction numbers of the native strain and mutant strain, R_{1wv} and R_{2wv} are given by, respectively,

$$\begin{aligned}
R_{1wv} &= \frac{\Lambda \beta_1 a_1}{\mu(\mu + a_1)(\mu + d_1 + \alpha_1 + \nu_1)}, \\
R_{2wv} &= \frac{\Lambda \beta_2 a_2}{\mu(\mu + a_2)(\mu + d_2 + \alpha_2)}.
\end{aligned}$$

Thus, the basic reproduction number of system without vaccination is given by $R_{0wv} = \max \{R_{1wv}, R_{2wv}\}$.

Theorem 4.2. If $R_0 = \max \{R_1, R_2\} < 1$, the DFE (D^0) is locally asymptotically stable; if $R_0 = \max \{R_1, R_2\} > 1$, D^0 is unstable.

Proof. By linearizing the system (1) at D^0 , we obtain the following characteristic equation

$$\begin{aligned}
(\lambda + \mu)^2(\lambda + p + \gamma + \mu)(\lambda^2 + \lambda(2\mu + a_1 + d_1 + \alpha_1) + (\mu + a_1)(\mu + d_1 + \alpha_1 + \nu_1)(1 - R_1)) \\
(\lambda^2 + \lambda(2\mu + a_2 + d_2 + \alpha_2) + (\mu + a_2)(\mu + d_2 + \alpha_2)(1 - R_2)) = 0.
\end{aligned} \tag{6}$$

From the above characteristic equation, it is easy to see that all the roots of Eq. (6) are negative or have negative real parts for $R_0 < 1$. Hence, the D^0 of system (1) is locally asymptotically stable for $R_0 < 1$. If $R_0 > 1$, at least one of the roots of Eq. (6) has positive real part. Hence, D^0 is unstable for $R_0 > 1$. \square

Theorem 4.3. D^0 is globally asymptotically stable, whenever $R_0 = \max\{R_1, R_2\} < 1$.

Proof. To prove the global stability of D^0 , we follow the approach given by Castillo-Chavez et al. [15]. We rewrite the system (1) as follows

$$\begin{aligned}\frac{dX}{dt} &= F(X, Y), \\ \frac{dY}{dt} &= G(X, Y), \quad G(X, 0) = 0,\end{aligned}\tag{7}$$

where $X = (S, V, R_1, R_2) \in \mathbb{R}^4$ signifies the number of uninfected individuals and $Y = (E_1, E_2, I_1, I_2) \in \mathbb{R}^4$ signifies the number of infected individuals. Disease-free equilibrium (D^0) is globally stable if the following two conditions are fulfilled:

(H1) For $\frac{dX}{dt} = F(X, Y)$, X^* is globally asymptotically stable,

(H2) $G(X, Y) = MY - \hat{G}(X, Y)$, $\hat{G}(X, Y) > 0$ for $(X, Y) \in \Delta$,

where $M = D_Y G(X^*, 0)$ is an M -matrix. For the system (1), we have

$$F(X, 0) = \begin{pmatrix} \Lambda - (\mu + p)S + \gamma V \\ pS - (\mu + \gamma)V \\ 0 \\ 0 \end{pmatrix}.\tag{8}$$

It is obvious that the equilibrium $X^* = \left(\frac{\Lambda(\mu+\gamma)}{\mu(\mu+\gamma+p)}, \frac{\Lambda p}{\mu(\mu+\gamma+p)}, 0, 0\right)$ is globally asymptotically stable of system (8). Further, for system (1), we obtain

$$\begin{aligned}M &= \begin{pmatrix} -(\mu + a_1) & 0 & \beta_1(S^0 + \delta_1 V^0) & 0 \\ 0 & -(\mu + a_2) & 0 & \beta_2(S^0 + \delta_2 V^0) \\ a_1 & 0 & -(\alpha_1 + \mu + d_1 + \nu_1) & 0 \\ 0 & a_2 & \nu_1 & -(\alpha_2 + \mu + d_2) \end{pmatrix}, \\ \hat{G}(X, Y) &= \begin{pmatrix} \beta_1 I_1((S^0 + \delta_1 V^0) - (S + \delta_1 V)) \\ \beta_2 I_2((S^0 + \delta_2 V^0) - (S + \delta_2 V + \delta_3 R_1)) \\ 0 \\ 0 \end{pmatrix}.\end{aligned}$$

It is clear that $\hat{G}(X, Y) \geq 0$. Hence, D^0 is globally stable, i.e. every solution of the system (1) approaches the DFE (D^0) as $t \rightarrow \infty$ for $R_0 < 1$. Thus, the disease (i.e., both native and mutant strains) will be eliminated from the community if $R_0 < 1$. Consequently, R_0 represents the threshold value for the existence of other positive equilibria of the system (1). Moreover, it is eminent that the basic reproduction number (R_0) represents the average number of secondary infections that occurred from a single infected individual in the whole susceptible population. Therefore, if $R_0 < 1$, each infected individual in the entire infectious period will produce less than one infected individual on average, which implies that the disease will die out. However, if $R_0 > 1$, then each infected individual in the whole infectious period having contact with susceptible individuals will generate more than one infected individual; this leads to the disease invading the susceptible population. \square

It must be mentioned that, for mathematical (endemic) models such as (1), the epidemiological necessity $R_0 < 1$ is sufficient as well as necessary for eradication of the disease. This is because, for such mathematical models (i.e., Kermack-McKendrick models with demographic

dynamics), the disease will persist whenever $R_0 > 1$ (this is because the pool of new susceptible individuals will continuously be refilled, by immigration or birth, thereby letting the disease to maintain itself in the community). If the demographic effects are not allowed (i.e., in the case of a single outbreak/epidemic model is used), the epidemiological condition $R_0 < 1$ is only sufficient, but not necessary, for eradicating the epidemic. For such epidemic models (with no demographic dynamics), the disease always dies out with time (irrespective of the value of the basic reproduction number of the epidemic models). In other words, even if the basic reproduction number exceeds unity, the disease will eventually die out; this is because the endemic rises and reach a peak.

4.2 Mutant dominant equilibrium and its stability

First of all, it should be mentioned that in the absence of native strain ($I_1 = 0$), the system (1) reduces to the following subsystem:

$$\begin{aligned}\frac{dS}{dt} &= \Lambda - \beta_2 I_2 S - (\mu + p)S + \gamma V, \\ \frac{dV}{dt} &= pS - \delta_2 \beta_2 I_2 V - (\mu + \gamma)V, \\ \frac{dE_2}{dt} &= \beta_2 (S + \delta_2 V) I_2 - (a_2 + \mu)E_2, \\ \frac{dI_2}{dt} &= a_2 E_2 - (\alpha_2 + \mu + d_2)I_2, \\ \frac{dR_2}{dt} &= \alpha_2 I_2 - \mu R_2.\end{aligned}\tag{9}$$

The analysis of the sub-system (9) will be considered in the following positively invariant region

$$\Delta_{I_2} = \left\{ (S, V, E_2, I_2, R_2) \in \mathbb{R}_+^5 : 0 < S + V + E_2 + I_2 + R_2 \leq \frac{\Lambda}{\mu} \subset \mathbb{R}_+^5 \right\}.$$

The mutant dominant equilibrium is given by $D^2 = (S^2, V^2, 0, E_2^2, 0, I_2^2, 0, R_2^2)$, where the components of D^2 can be obtained by solving the equations of right hand side of the subsystem (9). Thus,

$$\begin{aligned}S^2 &= \frac{\Lambda}{\mu} - \frac{p \{ \Lambda a_2 - (a_2 + \mu)(\alpha_2 + \mu + d_2)I_2^2 \}}{\mu a_2 (\delta_2 \beta_2 I_2^2 + \mu + \gamma + p)} - \frac{(a_2 + \mu)(\alpha_2 + \mu + d_2)I_2^2}{\mu a_2}, \\ V^2 &= \frac{p \{ \Lambda a_2 - (a_2 + \mu)(\alpha_2 + \mu + d_2)I_2^2 \}}{\mu a_2 (\delta_2 \beta_2 I_2^2 + \mu + \gamma + p)}, \quad E_2^2 = \frac{(\alpha_2 + \mu + d_2)I_2^2}{a_2}, \quad R_2^2 = \frac{\alpha_2 I_2^2}{\mu},\end{aligned}$$

and I_2^2 satisfies the following equation:

$$k_1' I_2^2 + k_2' I_2 + k_3' = 0,\tag{10}$$

where

$$\begin{aligned}k_1' &= \beta_2^2 (\mu + a_2) (\mu + d_2 + \alpha_2) \delta_2, \\ k_2' &= \beta_2 ((\mu + a_2) (\mu + d_2 + \alpha_2) (\gamma + \mu + (p + \mu) \delta_2) - \Lambda \beta_2 a_2 \delta_2), \\ k_3' &= \mu (\mu + a_2) (\mu + d_2 + \alpha_2) (\gamma + \mu + p) (1 - R_2).\end{aligned}$$

We can see that Eq. (10) has zero, one, or two roots, depending on parameter values. For the case $0 < \delta_2 \leq 1$, $k_3' < 0$ if $R_2 > 1$, and $k_3' > 0$ if $R_2 < 1$. Since Eq. (10) is quadratic equation,

therefore if $R_2 > 1$, then Eq. (10) has a unique positive root and there is a unique mutant dominant equilibrium. If $R_2 = 1$, then $k'_3 = 0$ and there is unique non-zero solution of (10), given by $I_2^2 = -\frac{k'_2}{k_1}$, which is positive if and only if $k'_2 < 0$. If $R_2 = 1, k'_3 = 0$, then

$$\Lambda\beta_2a_2(\gamma + \mu + p\delta_2) = \mu(\mu + a_2)(\mu + d_2 + \alpha_2)(p + \gamma + \mu). \quad (11)$$

The condition $k'_2 < 0$ gives

$$(\mu + a_2)(\mu + d_2 + \alpha_2)(\gamma + \mu + (p + \mu)\delta_2) < \Lambda\beta_2a_2\delta_2,$$

combined with (11), we obtain

$$(\gamma + \mu)^2 + (p\delta_2)^2 + \mu p\delta_2^2 + 2\gamma p\delta_2 + \mu p\delta_2 < 0,$$

which is not possible. Hence, if $R_2 \leq 1$, system (1) has no mutant dominant equilibrium. Furthermore, it should be stated that for the equilibrium D^2 to exist, it is necessary that the native strain dies out asymptotically (i.e., $R_1 \leq 1$). Thus, we conclude that system (9) has a unique mutant dominant equilibrium (D^2) whenever $R_2 > 1$ and $R_1 \leq 1$. Further, for the stability of the equilibrium D^2 , we have the following result:

Theorem 4.4. *The unique mutant dominant equilibrium (D^2) is globally asymptotically stable whenever $R_2 > 1$ and $R_1 \leq 1$.*

Proof. We consider

$$x = \frac{S}{S^2}, \quad y = \frac{V}{V^2}, \quad z = \frac{E_2}{E_2^2}, \quad u = \frac{I_2}{I_2^2},$$

and with the help of Eqs. of right hand side of the system (9), the system (9) can be rewritten as follows:

$$\begin{aligned} x' &= x \left[\frac{\Lambda}{S^2} \left(\frac{1}{x} - 1 \right) - \beta_2 I_2^2 (u - 1) + \frac{\gamma V^2}{S^2} \left(\frac{y}{x} - 1 \right) \right], \\ y' &= y \left[\frac{p S^2}{V^2} \left(\frac{x}{y} - 1 \right) - \delta_2 \beta_2 I_2^2 (u - 1) \right], \\ z' &= z \frac{\beta_2 I_2^2}{E_2^2} \left[S^2 \left(\frac{xu}{z} - 1 \right) + \delta_2 V^2 \left(\frac{yu}{z} - 1 \right) \right], \\ u' &= u \frac{a_2 E_2^2}{I_2^2} \left[\frac{z}{u} - 1 \right]. \end{aligned} \quad (12)$$

Further, we consider the following Lyapunov function

$$Z = k_1 S^2 (x - 1 - \ln x) + k_2 V^2 (y - 1 - \ln y) + k_3 E_2^2 (z - 1 - \ln z) + k_4 I_2^2 (u - 1 - \ln u),$$

where the positive constants k_1, k_2, k_3 , and k_4 will be defined below. By differentiating Z with respect to t along the solutions of (9), we obtain

$$\begin{aligned}
Z' &= k_1(x-1) \left[\Lambda \left(\frac{1}{x} - 1 \right) - \beta_2 S^2 I_2^2 (u-1) + \gamma V^2 \left(\frac{y}{x} - 1 \right) \right] \\
&\quad + k_2(y-1) \left[p S^2 \left(\frac{x}{y} - 1 \right) - \delta_2 \beta_2 V^2 I_2^2 (u-1) \right] \\
&\quad + k_3 \beta_2 I_2^2 (z-1) \left[S^2 \left(\frac{xu}{z} - 1 \right) + \delta_2 V^2 \left(\frac{yu}{z} - 1 \right) \right] + k_4 a_2 E_2^2 (u-1) \left(\frac{z}{u} - 1 \right) \\
&= k_1(2\Lambda + \gamma V^2 - \beta_2 S^2 I_2^2) + k_2(p S^2 - \delta_2 \beta_2 V^2 I_2^2) + k_3(\beta_2 S^2 I_2^2 + \delta_2 \beta_2 V^2 I_2^2) \\
&\quad + k_4 a_2 E_2^2 - (k_1 \Lambda + k_1 \gamma V^2 - k_1 \beta_2 S^2 I_2^2 - k_2 p S^2) x - k_1 \Lambda \frac{1}{x} \\
&\quad - (-k_1 \gamma V^2 + k_2 p S^2 - k_2 \delta_2 \beta_2 V^2 I_2^2) y - k_1 \gamma V^2 \frac{y}{x} - k_2 p S^2 \frac{x}{y} \\
&\quad - (k_1 \beta_2 S^2 I_2^2 - k_3 \beta_2 S^2 I_2^2) u x - (-k_1 \beta_2 S^2 I_2^2 - k_2 \delta_2 \beta_2 V^2 I_2^2 + k_4 a_2 E_2^2) u \\
&\quad - (k_2 \delta_2 \beta_2 V^2 I_2^2 - k_3 \delta_2 \beta_2 V^2 I_2^2) y u - (k_3 \beta_2 S^2 I_2^2 + k_3 \delta_2 \beta_2 V^2 I_2^2 - k_4 a_2 E_2^2) z \\
&\quad - k_3 \beta_2 S^2 I_2^2 \frac{xu}{z} - k_3 \delta_2 \beta_2 V^2 I_2^2 \frac{yu}{z} - k_4 a_2 E_2^2 \frac{z}{u} \\
&=: G(x, y, z, u).
\end{aligned}$$

Choose the positive constants k_1, k_2, k_3 , and k_4 as follows:

$$k_1 = k_2 = k_3 = 1, k_4 = \frac{a_2 + \mu}{a_2}.$$

Substituting the above values into the function $G(x, y, z, u)$ gives

$$\begin{aligned}
G(x, y, z, u) &= 2\Lambda + \gamma V^2 + p S^2 + (a_2 + \mu) E_2^2 - \mu S^2 x - \Lambda \frac{1}{x} - \mu V^2 y - \gamma V^2 \frac{y}{x} \\
&\quad - p S^2 \frac{x}{y} - \beta_2 S^2 I_2^2 \frac{xu}{z} - \delta_2 \beta_2 V^2 I_2^2 \frac{yu}{z} - (a_2 + \mu) E_2^2 \frac{z}{u} \\
&= \mu S^2 \left(2 - x - \frac{1}{x} \right) + \gamma V^2 \left(2 - \frac{x}{y} - \frac{y}{x} \right) + \mu V^2 \left(3 - \frac{1}{x} - y - \frac{x}{y} \right) \\
&\quad + \beta_2 S^2 I_2^2 \left(3 - \frac{1}{x} - \frac{xu}{z} - \frac{z}{u} \right) + \delta_2 \beta_2 V^2 I_2^2 \left(4 - \frac{1}{x} - \frac{x}{y} - \frac{yu}{z} - \frac{z}{u} \right).
\end{aligned}$$

By the property that the arithmetic mean is greater than or equal to the geometric mean, $G(x, y, z, u) \leq 0$, and the equality holds only for $x = y = 1$ and $z = u$, i.e.,

$$\{(x, y, z, u) \in \Delta_{I_2} : G(x, y, z, u) = 0\} \equiv \{(x, y, z, u) : x = y = 1, z = u\},$$

which corresponds to the set

$$\Delta'_{I_2} = \left\{ (S, V, E_2, I_2) : S = S^*, V = V^*, \frac{E_2}{E_2^*} = \frac{I_2}{I_2^*} \right\} \subset \Delta_{I_2} \subset \Delta.$$

It is evident to see that the maximum invariant set of (9) on the set Δ'_{I_2} is the singleton $\{D^2\}$, then the mutant dominant equilibrium D^2 is globally stable in $\Delta_{I_2} \subset \Delta$ by LaSalle's Invariance Principle [40]. \square

4.3 Coexistence equilibrium and its stability

This section examines the existence and global stability of the coexistence equilibrium of system (1). First of all, let us consider the endemic equilibrium $D^* = (S^*, V^*, E_1^*, E_2^*, I_1^*, I_2^*, R_1^*, R_2^*)$,

then $S^*, V^*, E_1^*, E_2^*, I_1^*, I_2^*, R_1^*$, and R_2^* satisfy the following equations:

$$\begin{aligned}
\Lambda - \beta_1 I_1 S - \beta_2 I_2 S - (\mu + p)S + \gamma V &= 0, \\
pS - \delta_1 \beta_1 I_1 V - \delta_2 \beta_2 I_2 V - (\mu + \gamma)V &= 0, \\
\beta_1 (S + \delta_1 V) I_1 - (a_1 + \mu)E_1 &= 0, \\
\beta_2 (S + \delta_2 V + \delta_3 R_1) I_2 - (a_2 + \mu)E_2 &= 0, \\
a_1 E_1 - (\alpha_1 + \mu + d_1 + \nu_1) I_1 &= 0, \\
a_2 E_2 - (\alpha_2 + \mu + d_2) I_2 + \nu_1 I_1 &= 0, \\
\alpha_1 I_1 - \delta_3 \beta_2 I_2 R_1 - \mu R_1 &= 0, \\
\alpha_2 I_2 - \mu R_2 &= 0.
\end{aligned} \tag{13}$$

The above Eqs (13) lead the following expressions:

$$\begin{aligned}
S^* &= \frac{\Lambda(\beta_1 \delta_1 I_1^* + \beta_2 \delta_2 I_2^* + \mu + \gamma)}{(\beta_1 I_1^* + \beta_2 I_2^* + \mu + p)(\beta_1 \delta_1 I_1^* + \beta_2 \delta_2 I_2^* + \mu + \gamma) - p\gamma}, \\
V^* &= \frac{\Lambda p}{(\beta_1 I_1^* + \beta_2 I_2^* + \mu + p)(\beta_1 \delta_1 I_1^* + \beta_2 \delta_2 I_2^* + \mu + \gamma) - p\gamma}, \\
E_1^* &= \frac{(\alpha_1 + \mu + d_1 + \nu_1) I_1^*}{a_1}, \quad E_2^* = \frac{(\alpha_2 + \mu + d_2) I_2^* - \nu_1 I_1^*}{a_2}, \\
R_1^* &= \frac{\alpha_1 I_1^*}{\delta_3 \beta_2 I_2^* + \mu}, \quad R_2^* = \frac{\alpha_2 I_2^*}{\mu},
\end{aligned}$$

and I_1^*, I_2^* are the solutions of the following equations:

$$\begin{aligned}
F(I_1, I_2) &\equiv \beta_2^2 \delta_2 I_2^2 + \beta_2 \left(-\frac{\Lambda \beta_1 a_1 \delta_2}{(\mu + a_1)(\mu + d_1 + \alpha_1 + \nu_1)} + \gamma + \mu + (p + \mu) \delta_2 + \beta_1 (\delta_1 + \delta_2) I_1 \right) I_2 \\
&\quad + \beta_1^2 \delta_1 I_1^2 + \beta_1 \left(-\frac{\Lambda \beta_1 a_1 \delta_1}{(\mu + a_1)(\mu + d_1 + \alpha_1 + \nu_1)} + \gamma + \mu + (p + \mu) \delta_1 \right) I_1 \\
&\quad + \mu(p + \mu + \gamma)(1 - R_1) = 0, \\
G(I_1, I_2) &\equiv I_2^3 \left(\beta_2^2 \delta_2 \left(1 - \frac{\Lambda a_2 \beta_2 \delta_2}{(\mu + a_2)(\mu + d_2 + \alpha_2)} - \frac{a_2 \alpha_1 \beta_2 \delta_3 I_1}{(\mu + a_2)(\mu + d_2 + \alpha_2)} \right) \right) \\
&\quad + I_2^2 \left(\beta_2 (\gamma + \mu + \delta_2 (p + \mu)) - \frac{a_2 \beta_2^2 \delta_2 \Lambda (\gamma + 2\mu - p \delta_2)}{(\mu + a_2)(\mu + d_2 + \alpha_2)} - \frac{I_1^2 a_2 \alpha_1 \beta_1 \beta_2^2 \delta_3 (\delta_1 + \delta_2)}{(\mu + a_2)(\mu + d_2 + \alpha_2)} \right. \\
&\quad \left. + I_1 \left(\beta_1 \beta_2 (\delta_1 + \delta_2) - \frac{\beta_2^2 (a_2 \alpha_1 \delta_3 (\gamma + \mu + (p + \mu) \delta_2) + \Lambda a_2 \beta_1 \delta_1 \delta_2 + (\mu + a_2) \delta_1 \nu_1)}{(\mu + a_2)(\mu + d_2 + \alpha_2)} \right) \right) \\
&\quad + I_2 \left(\mu(p + \gamma + \mu) - \frac{\Lambda \beta_2 a_2 \mu (\gamma + \mu + p \delta_2)}{(\mu + a_2)(\mu + d_2 + \alpha_2)} - \frac{a_2 \alpha_1 \beta_1^2 \beta_2 \delta_1 \delta_3 I_1^3}{(\mu + a_2)(\mu + d_2 + \alpha_2)} \right. \\
&\quad \left. + I_1^2 \left(1 - \frac{\beta_1 \beta_2 \delta_3 \alpha_1 a_2 (\gamma + \mu + (p + \mu) \delta_1)}{(\mu + a_2)(\mu + d_2 + \alpha_2)} + \frac{(\delta_1 + \delta_2) \nu_1}{(\mu + d_2 + \alpha_2)} \right) \right. \\
&\quad \left. + I_1 \left(\frac{\nu_1 (\gamma + \mu + (p + \mu) \delta_2) - \beta_2 \mu a_2 \alpha_1 \delta_3 (\gamma + \mu + p) - \Lambda \mu a_2 \beta_1 \beta_2 \delta_1}{(\mu + a_2)(\mu + d_2 + \alpha_2)} \right. \right. \\
&\quad \left. \left. + \beta_1 (\gamma + \mu + (p + \mu) \delta_1) \right) \right) - \frac{I_1}{(\mu + d_2 + \alpha_2)} \left(\nu_1 \mu (p + \gamma + \mu) \right. \\
&\quad \left. + I_1 \beta_1 \nu_1 (\gamma + \mu + (p + \mu) \delta_1) + I_1^2 \beta_1^2 \delta_1 \nu_1 \right) = 0.
\end{aligned} \tag{14}$$

If the system (14) admits a solution, then the system (1) will have an endemic equilibrium. Obtaining the explicit expression for the exact solution of the non-linear autonomous system

(14) is a daunting task. However, we prove the global stability of the endemic equilibrium for the special case ($\delta_3 = 0$ and $\nu_1 = 0$) of system (1) in the subsequent theorem:

Theorem 4.5. *If the endemic equilibrium $D^* = (S^*, V^*, E_1^*, E_2^*, I_1^*, I_2^*, R_1^*, R_2^*)$ exists for $\delta_3 = 0$ and $\nu_1 = 0$, then it is globally asymptotically stable.*

Proof. For $\delta_3 = 0$ and $\nu_1 = 0$, the endemic equilibrium $D^* = (S^*, V^*, E_1^*, E_2^*, I_1^*, I_2^*)$, $S^*, V^*, E_1^*, E_2^*, I_1^*$, and I_2^* satisfy the following equations:

$$\begin{aligned} \Lambda - \beta_1 I_1 S - \beta_2 I_2 S - (\mu + p)S + \gamma V &= 0, \\ pS - \delta_1 \beta_1 I_1 V - \delta_2 \beta_2 I_2 V - (\mu + \gamma)V &= 0, \\ \beta_1 (S + \delta_1 V) I_1 - (a_1 + \mu) E_1 &= 0, \\ \beta_2 (S + \delta_2 V) I_2 - (a_2 + \mu) E_2 &= 0, \\ a_1 E_1 - (\alpha_1 + \mu + d_1) I_1 &= 0, \\ a_2 E_2 - (\alpha_2 + \mu + d_2) I_2 &= 0. \end{aligned} \tag{15}$$

Since R_1 and R_2 do not appear explicitly in the first six equations, therefore we omit them. By applying Eq. (15) and denoting

$$x = \frac{S}{S^*}, \quad y = \frac{V}{V^*}, \quad z = \frac{E_1}{E_1^*}, \quad u = \frac{E_2}{E_2^*}, \quad v = \frac{I_1}{I_1^*}, \quad w = \frac{I_2}{I_2^*},$$

the system (1) can be rewritten as follows:

$$\begin{aligned} x' &= x \left[\frac{\Lambda}{S^*} \left(\frac{1}{x} - 1 \right) - \beta_1 I_1^* (v - 1) - \beta_2 I_2^* (w - 1) + \frac{\gamma V^*}{S^*} \left(\frac{y}{x} - 1 \right) \right], \\ y' &= y \left[\frac{p S^*}{V^*} \left(\frac{x}{y} - 1 \right) - \delta_1 \beta_1 I_1^* (v - 1) - \delta_2 \beta_2 I_2^* (w - 1) \right], \\ z' &= z \frac{\beta_1 I_1^*}{E_1^*} \left[S^* \left(\frac{xv}{z} - 1 \right) + \delta_1 V^* \left(\frac{yv}{z} - 1 \right) \right], \\ u' &= u \frac{\beta_2 I_2^*}{E_2^*} \left[S^* \left(\frac{xw}{u} - 1 \right) + \delta_2 V^* \left(\frac{yw}{u} - 1 \right) \right], \\ v' &= v \frac{a_1 E_1^*}{I_1^*} \left[\frac{z}{v} - 1 \right], \\ w' &= w \frac{a_2 E_2^*}{I_2^*} \left[\frac{u}{w} - 1 \right]. \end{aligned} \tag{16}$$

It is clear that the endemic equilibrium D^* of (1) corresponds to the positive equilibrium $\bar{D}^*(1, 1, 1, 1, 1, 1)$ of (16), and that the global stability of \bar{D}^* is same as that of D^* , therefore, we will discuss the global stability of the equilibrium \bar{D}^* of system (16) instead of D^* .

Define the Lyapunov function

$$\begin{aligned} L &= k_1 S^* (x - 1 - \ln x) + k_2 V^* (y - 1 - \ln y) + k_3 E_1^* (z - 1 - \ln z) + k_4 E_2^* (u - 1 - \ln u) \\ &\quad + k_5 I_1^* (v - 1 - \ln v) + k_6 I_2^* (w - 1 - \ln w), \end{aligned}$$

where the positive numbers k_1, k_2, k_3, k_4, k_5 , and k_6 will be given below, then differentiating L

with respect to t along solutions of (16), we obtain

$$\begin{aligned}
L' &= k_1(x-1) \left[\Lambda \left(\frac{1}{x} - 1 \right) - \beta_1 I_1^* S^*(v-1) - \beta_2 I_2^* S^*(w-1) + \gamma V^* \left(\frac{y}{x} - 1 \right) \right] \\
&\quad + k_2(y-1) \left[p S^* \left(\frac{x}{y} - 1 \right) - \delta_1 \beta_1 I_1^* V^*(v-1) - \delta_2 \beta_2 I_2^* V^*(w-1) \right] \\
&\quad + k_3(z-1) \beta_1 I_1^* \left[S^* \left(\frac{xv}{z} - 1 \right) + \delta_1 V^* \left(\frac{yv}{z} - 1 \right) \right] \\
&\quad + k_4(u-1) \beta_2 I_2^* \left[S^* \left(\frac{xw}{u} - 1 \right) + \delta_2 V^* \left(\frac{yw}{u} - 1 \right) \right] \\
&\quad + k_5(v-1) a_1 E_1^* \left[\frac{z}{v} - 1 \right] + k_6(w-1) a_2 E_2^* \left[\frac{u}{w} - 1 \right] \\
&= k_1(2\Lambda - \beta_1 S^* I_1^* - \beta_2 S^* I_2^* + \gamma V^*) + k_2(p S^* - \delta_1 \beta_1 V^* I_1^* - \delta_2 \beta_2 V^* I_2^*) \\
&\quad + k_3(\beta_1 S^* I_1^* + \delta_1 \beta_1 V^* I_1^*) + k_4(\beta_2 S^* I_2^* + \delta_2 \beta_2 V^* I_2^*) + k_5 a_1 E_1^* + k_6 a_2 E_2^* \\
&\quad - (k_1 \Lambda - k_1 \beta_1 S^* I_1^* - k_1 \beta_2 S^* I_2^* + k_1 \gamma V^* - k_2 p S^*) x - k_1 \Lambda \frac{1}{x} \\
&\quad - (-k_1 \gamma V^* + k_2 p S^* - k_2 \delta_1 \beta_1 V^* I_1^* - k_2 \delta_2 \beta_2 V^* I_2^*) y - (k_1 \beta_1 S^* I_1^* - k_3 \beta_1 S^* I_1^*) x v \\
&\quad - (-k_1 \beta_1 S^* I_1^* - k_2 \delta_1 \beta_1 V^* I_1^* + k_5 a_1 E_1^*) v - (k_1 \beta_2 S^* I_2^* - k_4 \beta_2 S^* I_2^*) x w \\
&\quad - (-k_1 \beta_2 S^* I_2^* - k_2 \delta_2 \beta_2 V^* I_2^* + k_6 a_2 E_2^*) w - k_1 \gamma V^* \frac{y}{x} - k_2 p S^* \frac{x}{y} - k_3 \beta_1 S^* I_1^* \frac{xv}{z} \\
&\quad - k_3 \beta_1 \delta_1 V^* I_1^* \frac{yv}{z} - k_4 \beta_2 S^* I_2^* \frac{xw}{u} - k_4 \beta_2 \delta_2 V^* I_2^* \frac{yw}{u} - (k_1 \delta_1 \beta_1 V^* I_1^* - k_3 \delta_1 \beta_1 V^* I_1^*) y v \\
&\quad - (k_2 \delta_2 \beta_2 V^* I_2^* - k_4 \delta_2 \beta_2 V^* I_2^*) y w - (k_3 \beta_1 S^* I_1^* + k_3 \beta_1 \delta_1 V^* I_1^* - k_5 a_1 E_1^*) z \\
&\quad - (k_4 \beta_2 S^* I_2^* + k_4 \beta_2 \delta_2 V^* I_2^* - k_6 a_2 E_2^*) u - k_5 a_1 E_1^* \frac{z}{v} - k_6 a_2 E_2^* \frac{u}{w} \\
&=: F(x, y, z, u, v, w).
\end{aligned}$$

Now we choose the positive constants $k_1, k_2, k_3, k_4, k_5, k_6$ as follows:

$$k_1 = k_2 = k_3 = k_4 = 1, \quad k_5 = \frac{a_1 + \mu}{a_1}, \quad k_6 = \frac{a_2 + \mu}{a_2}.$$

Substituting them into the function $F(x, y, z, u, v, w)$ gives

$$\begin{aligned}
F(x, y, z, u, v, w) &= [2\Lambda + \gamma V^* + p S^* + (a_1 + \mu) E_1^* + (a_2 + \mu) E_2^*] - \mu S^* x - \Lambda \frac{1}{x} - \mu V^* y \\
&\quad - \gamma V^* \frac{y}{x} - p S^* \frac{x}{y} - \beta_1 S^* I_1^* \frac{xv}{z} - \delta_1 \beta_1 V^* I_1^* \frac{yv}{z} - \beta_2 S^* I_2^* \frac{xw}{u} \\
&\quad - \delta_2 \beta_2 V^* I_2^* \frac{yw}{u} - (a_1 + \mu) E_1^* \frac{z}{v} - (a_2 + \mu) E_2^* \frac{u}{w} \\
&= \mu S^* \left(2 - x - \frac{1}{x} \right) + \gamma V^* \left(2 - \frac{x}{y} - \frac{y}{x} \right) + \mu V^* \left(3 - y - \frac{1}{x} - \frac{x}{y} \right) \\
&\quad + \beta_1 S^* I_1^* \left(3 - \frac{1}{x} - \frac{xv}{z} - \frac{z}{v} \right) + \beta_2 S^* I_2^* \left(3 - \frac{1}{x} - \frac{xw}{u} - \frac{u}{w} \right) \\
&\quad + \delta_2 \beta_2 V^* I_2^* \left(4 - \frac{1}{x} - \frac{x}{y} - \frac{yw}{u} - \frac{u}{w} \right) + \delta_1 \beta_1 V^* I_1^* \left(4 - \frac{1}{x} - \frac{x}{y} - \frac{yv}{z} - \frac{z}{v} \right).
\end{aligned}$$

Here, clearly $F(x, y, z, u, v, w) \leq 0$, and the equality holds only for $x = y = 1$, $z = v$, and $u = w$, i.e.,

$$\{(x, y, z, u, v, w) \in \Delta : F(x, y, z, u, v, w) = 0\} \equiv \{(x, y, z, u, v, w) : x = y = 1, z = v, u = w\},$$

which corresponds to the set

$$\Delta' = \left\{ (S, V, E_1, E_2, I_1, I_2) : S = S^*, V = V^*, \frac{E_1}{E_1^*} = \frac{I_1}{I_1^*}, \frac{E_2}{E_2^*} = \frac{I_2}{I_2^*} \right\} \subset \Delta.$$

It is evident to see that the maximum invariant set on the set Δ' is the singleton $\{D^*\}$, then the endemic equilibrium D^* is globally stable in Δ by LaSalle's Invariance Principle [40]. \square

4.4 Bifurcations

Different dynamical behaviors may occur in a mathematical model for the variation of the model parameters. The critical parameter value at which qualitative dynamics change occurs is called a bifurcation point. The objective of this section is to determine some local bifurcations of the system (1) with the variation of different parameters.

4.4.1 Hopf bifurcation

This section focuses on the local stability and Hopf bifurcation at the positive equilibrium D^* of system (1), which represents the coexistence of the both strains (native and mutant). To determine the local asymptotic stability of D^* , the characteristic equation of the linearized system of (1) at D^* is utilized. The characteristic equation is given by

$$C(\lambda) = \lambda^7 + l_1\lambda^6 + l_2\lambda^5 + l_3\lambda^4 + l_4\lambda^3 + l_5\lambda^2 + l_6\lambda + l_7 = 0, \quad (17)$$

where $l_1, l_2, l_3, l_4, l_5, l_6$, and l_7 are given in Appendix A. Now, we define Routh-Hurwitz determinants

$$\begin{aligned} H_1 &= l_1, \quad H_2 = \begin{vmatrix} l_1 & l_3 \\ 1 & l_2 \end{vmatrix}, \quad H_3 = \begin{vmatrix} l_1 & l_3 & l_5 \\ 1 & l_2 & l_4 \\ 0 & l_1 & l_3 \end{vmatrix}, \quad H_4 = \begin{vmatrix} l_1 & l_3 & l_5 & l_7 \\ 1 & l_2 & l_4 & l_6 \\ 0 & l_1 & l_3 & l_5 \\ 0 & 1 & l_2 & l_4 \end{vmatrix}, \\ H_5 &= \begin{vmatrix} l_1 & l_3 & l_5 & l_7 & 0 \\ 1 & l_2 & l_4 & l_6 & 0 \\ 0 & l_1 & l_3 & l_5 & l_7 \\ 0 & 1 & l_2 & l_4 & l_6 \\ 0 & 0 & l_1 & l_3 & l_5 \end{vmatrix}, \quad H_6 = \begin{vmatrix} l_1 & l_3 & l_5 & l_7 & 0 & 0 \\ 1 & l_2 & l_4 & l_6 & 0 & 0 \\ 0 & l_1 & l_3 & l_5 & l_7 & 0 \\ 0 & 1 & l_2 & l_4 & l_6 & 0 \\ 0 & 0 & l_1 & l_3 & l_5 & l_7 \\ 0 & 0 & 1 & l_2 & l_4 & l_6 \end{vmatrix}, \quad H_7 = l_7 H_6. \end{aligned}$$

By Routh-Hurwitz criterion, D^* is locally asymptotically stable (i.e. $Re(\lambda) < 0$) if and only if $H_1 > 0, H_2 > 0, H_3 > 0, H_4 > 0, H_5 > 0, H_6 > 0$, and $H_7 > 0$; otherwise, D^* becomes unstable.

Further, we determine the occurrence conditions of Hopf bifurcation of system (1). To study the Hopf bifurcation, bifurcation parameter should be chosen at first. Among all parameters of system (1), we choose the parameter ν_1 , which represents the mutation rate of the native strain. With the other parameter values given, we can calculate the threshold value of the bifurcation parameter ν_1 . In the following, we denote this threshold value of Hopf bifurcation point as $\nu_1 = \nu_1^*$.

By Liu criterion [46], we assume that there is a smooth curve of equilibrium points $(D(\nu_1), \nu_1^*)$ with $D(\nu_1) = \nu_1^*$ for system (1) and (D^*, ν_1^*) is a positive equilibrium point. If $C(\lambda, \nu_1^*) = \lambda^7 + l_1(\nu_1^*)\lambda^6 + l_2(\nu_1^*)\lambda^5 + l_3(\nu_1^*)\lambda^4 + l_4(\nu_1^*)\lambda^3 + l_5(\nu_1^*)\lambda^2 + l_6(\nu_1^*)\lambda + l_7(\nu_1^*)$ is the characteristic equation at (D^*, ν_1^*) , then for a simple Hopf bifurcation, we have the following conditions:

- (i) $l_7(\nu_1^*) > 0, H_1(\nu_1^*) > 0, H_2(\nu_1^*) > 0, H_3(\nu_1^*) > 0, H_4(\nu_1^*) > 0, H_5(\nu_1^*) > 0$, and $H_6(\nu_1^*) = 0$.

$$(ii) \frac{d}{d\nu_1}(H_6(\nu_1^*)) \neq 0,$$

where $H_1(\nu_1^*)$, $H_2(\nu_1^*)$, $H_3(\nu_1^*)$, $H_4(\nu_1^*)$, $H_5(\nu_1^*)$, and $H_6(\nu_1^*)$ are the Hurwitz determinants at the bifurcation parameter ν_1^* .

If the condition (i) holds, then the characteristic polynomial have to meet the condition for a pair of purely imaginary eigenvalues. Now, to occurrence the Hopf bifurcation, we need to derive the transversality condition (ii). For this, we let $\pm i\omega$ be a pair of purely imaginary eigenvalues. Here, differentiating the characteristic equation (17) with respect to ν_1 , we obtain

$$(7\lambda^6 + 6l_1\lambda^5 + 5l_2\lambda^4 + 4l_3\lambda^3 + 3l_4\lambda^2 + 2l_5\lambda + l_6) \frac{d\lambda}{d\nu_1} + \lambda^6 \frac{dl_1}{d\nu_1} + \lambda^5 \frac{dl_2}{d\nu_1} + \lambda^4 \frac{dl_3}{d\nu_1} + \lambda^3 \frac{dl_4}{d\nu_1} + \lambda^2 \frac{dl_5}{d\nu_1} + \lambda \frac{dl_6}{d\nu_1} + \frac{dl_7}{d\nu_1} = 0.$$

Further, we obtain

$$\left(\frac{d\lambda}{d\nu_1} \right)^{-1} = - \frac{7\lambda^6 + 6l_1\lambda^5 + 5l_2\lambda^4 + 4l_3\lambda^3 + 3l_4\lambda^2 + 2l_5\lambda + l_6}{\lambda^6 \frac{dl_1}{d\nu_1} + \lambda^5 \frac{dl_2}{d\nu_1} + \lambda^4 \frac{dl_3}{d\nu_1} + \lambda^3 \frac{dl_4}{d\nu_1} + \lambda^2 \frac{dl_5}{d\nu_1} + \lambda \frac{dl_6}{d\nu_1} + \frac{dl_7}{d\nu_1}}.$$

Furthermore, we have

$$\begin{aligned} \text{sign} \left[\frac{d(Re(\lambda))}{d\nu_1} \right]_{\lambda=i\omega, H_6=0} &= \text{sign} \left[Re \left(\frac{d\lambda}{d\nu_1} \right)^{-1} \right]_{\lambda=i\omega, H_6=0} \\ &= \text{sign}[\Upsilon], \end{aligned}$$

where,

$$\begin{aligned} \Upsilon &= Re \left[\frac{(7\omega^6 - 5l_2\omega^4 + 3l_4\omega^2 - l_6) + i(-6l_4\omega^5 + 4l_3\omega^2 - 2l_5\omega)}{(-\omega^6 \frac{dl_1}{d\nu_1} + \omega^4 \frac{dl_3}{d\nu_1} - \omega^2 \frac{dl_5}{d\nu_1} + \frac{dl_7}{d\nu_1}) + i(\omega^5 \frac{dl_2}{d\nu_1} - \omega^3 \frac{dl_4}{d\nu_1} + \omega \frac{dl_6}{d\nu_1})} \right] = \frac{M_1 M_3 + M_2 M_4}{M_3^2 + M_4^2}, \\ M_1 &= 7\omega^6 - 5l_2\omega^4 + 3l_4\omega^2 - l_6, \quad M_2 = -6l_4\omega^5 + 4l_3\omega^2 - 2l_5\omega, \\ M_3 &= -\omega^6 \frac{dl_1}{d\nu_1} + \omega^4 \frac{dl_3}{d\nu_1} - \omega^2 \frac{dl_5}{d\nu_1} + \frac{dl_7}{d\nu_1}, \quad M_4 = \omega^5 \frac{dl_2}{d\nu_1} - \omega^3 \frac{dl_4}{d\nu_1} + \omega \frac{dl_6}{d\nu_1}. \end{aligned}$$

If $M_1 M_3 + M_2 M_4 > 0$, then $\text{sign} \left[\frac{d(Re(\lambda))}{d\nu_1} \right]_{\nu_1=\nu_1^*} > 0$ and the transversality condition (ii) holds.

Summarizing the above discussion, we obtain the subsequent theorem:

Theorem 4.6. *For the existing positive equilibrium D^* of system (1), the system (1) around D^* enters into Hopf bifurcation when ν_1 crosses through ν_1^* .*

4.4.2 Transcritical bifurcation

We see that Eq. (6) has a zero eigenvalue when either $R_1 = 1$ or $R_2 = 1$. Thus, the system (1) may undergo a transcritical bifurcation at D^0 when either $R_1 = 1$ or $R_2 = 1$. In this subsection, we establish conditions on the parameters using Theorem 4.1 from Castillo-Chavez and Song [16] and center manifold theory [26]. For the transcritical bifurcation, we establish the following theorem:

Theorem 4.7. *1. Assume $R_1 < 1$, the system (1) undergoes a transcritical bifurcation near D^0 , when $R_2 = 1$.*

2. Assume $R_2 < 1$, the system (1) undergoes a transcritical bifurcation near D^0 , when $R_1 = 1$.

Proof. 1. We choose β_2 as a bifurcation parameter. By solving $R_2 = 1$, we obtain

$$\beta_2 = \beta_2^* = \frac{\mu(a_2 + \mu)(\alpha_2 + d_2 + \mu)(\gamma + \mu + p)}{a_2\Lambda(\gamma + \mu + \delta_2 p)}.$$

It can easily be obtained that the Jacobian $J_{(D^0, \beta_2^*)}$ evaluated at D^0 and $\beta_2 = \beta_2^*$ has a simple zero eigenvalue and other eigenvalues have negative sign. Hence D^0 is a non-hyperbolic equilibrium, when $\beta_2 = \beta_2^*$. Now, we calculate a right eigenvector $W = (w_1, w_2, w_3, w_4, w_5, w_6)$ and a left eigenvector $V = (v_1, v_2, v_3, v_4, v_5, v_6)$ associated to the zero eigenvalues. Here

$$\begin{aligned} w_1 &= -\frac{(a_2 + \mu)(\alpha_2 + d_2 + \mu)((\gamma + \mu)^2 + \gamma\delta_2 p)}{a_2\mu(\gamma + \mu + p)(\gamma + \mu + \delta_2 p)}, \\ w_2 &= -\frac{p(a_2 + \mu)(\alpha_2 + d_2 + \mu)(\gamma + \mu + \delta_2(\mu + p))}{a_2\mu(\gamma + \mu + p)(\gamma + \mu + \delta_2 p)}, \\ w_3 &= 0, \quad w_4 = \frac{\mu + d_2 + \alpha_2}{a_2}, \quad w_5 = 0, \quad w_6 = 1, \quad w_7 = 0, \\ v_1 &= 0, \quad v_2 = 0, \quad v_3 = \frac{a_1\nu_1}{(\mu + a_1)(\mu + d_1 + \alpha_1 + \nu_1)(1 - R_1)}, \\ v_4 &= 1, \quad v_5 = \frac{\nu_1}{(\mu + d_1 + \alpha_1 + \nu_1)(1 - R_1)}, \quad v_6 = 1, \quad v_7 = 0. \end{aligned}$$

Now from Theorem 4.1 of [16], we need to calculate the bifurcation constants a and b . For system (1), the associated non-zero partial derivatives of f (evaluated at D^0 , $x_1 = S, x_2 = V, x_3 = E_1, x_4 = E_2, x_5 = I_1, x_6 = I_2, x_7 = R_1$) are given by

$$\begin{aligned} a &= 2v_3w_1w_5\frac{\partial^2 f_3}{\partial S\partial I_1} + 2v_3w_2w_5\frac{\partial^2 f_3}{\partial V\partial I_1} + 2v_4w_1w_6\frac{\partial^2 f_4}{\partial S\partial I_2} + 2v_4w_2w_6\frac{\partial^2 f_4}{\partial V\partial I_2} + 2v_4w_6w_7\frac{\partial^2 f_4}{\partial I_2\partial R_1} \\ &= 2v_4w_6(w_1 + \delta_2 w_2)\beta_2^* < 0, \\ b &= 2v_4w_6\frac{\partial^2 f_4}{\partial \beta_2\partial I_2} = 2v_4w_6(S^0 + \delta_2 V^0) > 0. \end{aligned}$$

Since the coefficient a is negative and b is positive, the direction of the bifurcation of system (1) at $\beta_2 = \beta_2^*$ is forward.

2. By choosing β_1 as a bifurcation parameter. By solving $R_1 = 1$, we obtain

$$\beta_1 = \beta_1^* = \frac{\mu(a_1 + \mu)(\gamma + \mu + p)(\alpha_1 + d_1 + \mu + \nu_1)}{a_1\Lambda(\gamma + \mu + \delta_1 p)}.$$

Following simple procedure of previous case, we obtain that D^0 is a non-hyperbolic equilibrium, when $\beta_1 = \beta_1^*$. Now, we calculate a right eigenvector $W_1 = (w_{11}, w_{22}, w_{33}, w_{44}, w_{55}, w_{66})$ and a left eigenvector $V_1 = (v_{11}, v_{22}, v_{33}, v_{44}, v_{55}, v_{66})$ associated to the zero eigenvalues. Here

$$\begin{aligned} w_{11} &= -\frac{\Lambda\beta_2((\gamma + \mu)^2 + p\gamma\delta_2)\nu_1}{\alpha_1\mu(p + \gamma + \mu)^2(\mu + d_2 + \alpha_2)(\mu + a_2)(1 - R_2)} - \frac{(a_1 + \mu)(\alpha_1 + d_1 + \mu + \nu_1)((\gamma + \mu)^2 + \gamma\delta_1 p)}{a_1\alpha_1(\gamma + \mu + p)(\gamma + \mu + \delta_1 p)}, \\ w_{22} &= -\frac{p(\gamma + \mu + (p + \mu)\delta_2)}{(p + \gamma + \mu)\alpha_1} \left(\frac{\Lambda\beta_2\nu_1}{\mu(p + \gamma + \mu)(\mu + d_2 + \alpha_2)(1 - R_2)} + \frac{(\mu + a_1)(\mu + d_1 + \alpha_1 + \nu_1)}{a_1(\gamma + \mu + p\delta_2)} \right), \\ w_{33} &= \frac{\mu(\alpha_1 + d_1 + \mu + \nu_1)}{a_1\alpha_1}, \quad w_{44} = \frac{\Lambda\beta_2(\gamma + \mu + p\delta_2)\nu_1}{\alpha_1(p + \gamma + \mu)(\mu + d_2 + \alpha_2)(\mu + a_2)(1 - R_2)}, \quad w_{55} = \frac{\mu}{\alpha_1}, \\ w_{66} &= \frac{\mu\nu_1}{\alpha_1(\mu + d_2 + \alpha_2)(1 - R_2)}, \quad w_{77} = 1, \quad v_{11} = 0, \quad v_{22} = 0, \quad v_{33} = \frac{a_1}{a_1 + \mu}, \quad v_{44} = 0, \\ v_{55} &= 1, \quad v_{66} = 0, \quad v_{77} = 0. \end{aligned}$$

Similarly, as in previous case, we have

$$\begin{aligned}
a &= 2v_{33}w_{11}w_{55}\frac{\partial^2 f_3}{\partial S\partial I_1} + 2v_{33}w_{22}w_{55}\frac{\partial^2 f_3}{\partial V\partial I_1} \\
&= 2v_{33}w_{11}w_{55}\beta_1^* + 2v_{33}w_{22}w_{55}\delta_1\beta_1^*, \\
&= 2v_{33}w_{55}\beta_1^*(w_{11} + \delta_1w_{22}) < 0, \\
b &= 2v_{33}w_{55}\frac{\partial^2 f_3}{\partial \beta_1\partial I_1} = 2v_{33}w_{55}(S^0 + \delta_1V^0) > 0.
\end{aligned}$$

Therefore again in this case, the direction of the bifurcation of system (1) at $\beta_1 = \beta_1^*$ is forward. \square

5 Implications for disease control

For vaccine-preventable diseases, not all susceptible individuals could be immunized for numerous reasons, such as they are too young to be vaccinated (vaccinating young children or infants can, sometimes, harm the children/infants), they have weakened immune system and co-morbidities (and vaccinating may make their prognosis worse), they are of higher age, or they opt out for religious or traditional reasons, cultural. However, the question is what is the smallest proportion of those individuals we can vaccinate that we need to vaccinate so that those we cannot vaccinate can be protected from emerging severe disease or dying of the disease. The idea of herd immunity in the disease dynamics is related to the indirect protection against acquiring of infectious disease, which members of the community obtain when a large percentage of the populace has become protected to the contagious disease due to natural recovery from prior infection or vaccination [3, 4, 21]. The outcome of herd immunity is that persons who are not immune (e.g., those who have not been infected yet or cannot be vaccinated) obtain some defense against acquiring the infection. The fastest and safest way to attain herd immunity is vaccination. It should, however, be stated that Sweden implemented the other procedure for achieving herd immunity in the COVID-19 dynamics in Sweden [23]. In other words, the Swedish public health agencies intended to achieve herd immunity by not employing the basic society transmission reduction strategies (e.g., community lockdowns, social distancing, contact tracing use of face masks in public, etc.) employed in almost every nation or community that is hard-hit with the COVID-19 pandemic, opting, instead, to let persons to attain disease and, hopefully, recover from it. In this section, a theoretical condition for achieving community-wide vaccine-induced herd immunity is obtained. Theorem 4.2 has significant public health implications. It reveals that if the imperfect vaccine has sufficient efficacy and coverage rate to make $R_0 < 1$, COVID-19 will be eradicated from society. The global stability of the disease-free equilibrium (Theorem 4.3) for $R_0 < 1$ confirms that such epidemics do not hit. This means R_0 is an appropriate combination of parameters to measure the efficiency of a vaccination campaign.

5.1 Herd immunity

Not every person in a given population expects to be immunized in order to eradicate the disease. A fraction of people with immunity in the given population required to stop an epidemic is named herd immunity. Let ρ represent the fraction of the vaccinated population at D^0 (the disease-free equilibrium). Then,

$$\rho = \frac{p}{\mu + \gamma + p}.$$

In the absence of vaccination, i.e., when $p = 0$, the basic reproduction number is given by R_{0wv} . Hence, we can write

$$R_0 = \max \{R_{1wv}(1 - (1 - \delta_1)\rho), R_{2wv}(1 - (1 - \delta_2)\rho)\}, \quad (18)$$

with $R_1 = R_{1wv}(1 - (1 - \delta_1)\rho)$, and $R_2 = R_{2wv}(1 - (1 - \delta_2)\rho)$. It is noted that $R_1 \leq R_{1wv}$, $R_2 \leq R_{2wv}$, and thus $R_0 \leq R_{0wv}$. The equality holds only $\rho = 0$ (i.e., $p = 0$) or $\delta_1 = \delta_2 = 1$. This indicates that the vaccine, even not 100% effective, will certainly reduce the basic reproduction number of the disease. Since $R_0 < 1$ is a necessary and sufficient condition for the eradication of disease (Theorems 4.2 and 4.3), hence it follows from (18) that

$$\rho > \max \left\{ \frac{1}{1 - \delta_1} \left(1 - \frac{1}{R_{1wv}} \right), \frac{1}{1 - \delta_2} \left(1 - \frac{1}{R_{2wv}} \right) \right\} = \rho_{critical} \quad (19)$$

is also a necessary and sufficient condition for disease elimination. Here, $\rho_{critical}$ signifies herd immunity. Although, this outcome could be achieved in the case of continuous vaccination and that herd immunity is attained if the vaccination rate is large enough such that ρ , the fraction of vaccinated individuals at the disease-free equilibrium, exceeds the critical value $\rho_{critical}$. Combining Theorems 4.2 and 4.3, we obtain the following consequence:

Proposition 5.1. *COVID-19 can be eradicated from the population if $\rho > \rho_{critical}$.*

The inequality (19) can be expressed in terms of the vaccination rate p . This is done by noting, first of all, that R_0 is a decreasing function of p ,

$$\frac{dR_0}{dp} = \max \left\{ \frac{-\Lambda(\gamma + \mu)(1 - \delta_1)a_1\beta_1}{\mu(p + \gamma + \mu)^2(\mu + a_1)(\mu + d_1 + \alpha_1 + \nu_1)}, \frac{-\Lambda(\gamma + \mu)(1 - \delta_2)a_2\beta_2}{\mu(p + \gamma + \mu)^2(\mu + a_2)(\mu + d_2 + \alpha_2)} \right\} < 0$$

and so it is minimized by letting p go to infinity. Taking the limit as p approaches infinity, we see that this expression is always greater than $\max \{\delta_1 R_{1wv}, \delta_2 R_{2wv}\}$. Thus, if $\max \{\delta_1 R_{1wv}, \delta_2 R_{2wv}\} > 1$, then no amount of vaccination can make R_0 smaller than unity. Alternatively, if $\max \{\delta_1 R_{1wv}, \delta_2 R_{2wv}\} < 1$, then the condition

$$p > \max \left\{ \frac{(\gamma + \mu)(R_{1wv} - 1)}{1 - \delta_1 R_{1wv}}, \frac{(\gamma + \mu)(R_{2wv} - 1)}{1 - \delta_2 R_{2wv}} \right\} = p_{critical} \quad (20)$$

gives $R_0 < 1$. Of course, this condition assumes $R_0 > 1$, since disease elimination follows without vaccination if $R_0 < 1$ (by Theorems 4.2 and 4.3 and the fact that $R_0 \leq R_{0wv}$). It is easy to show that from (20), we obtain $R_0 < 1$ if $p > p_{critical}$, and $R_0 > 1$ if $p < p_{critical}$. Thus, we have established the following result:

Proposition 5.2. *If $\max \{\delta_1 R_{1wv}, \delta_2 R_{2wv}\} < 1$ and $p > p_{critical}$, then COVID-19 will be eliminated from the community. If $\max \{\delta_1 R_{1wv}, \delta_2 R_{2wv}\} > 1$, then no amount of vaccination would be able to prevent the COVID-19 outbreak in the community.*

6 Numerical illustration

In this section, we investigate the dynamics of system (1) numerically for different sets of parameter values. Such investigations aim to determine the effect of varying the values of the different parameters and support the obtained theoretical results. It is observed that the hypothetical values of parameters given in Table 2 are biologically feasible. However, to verify the bifurcations and different dynamical behavior of system (1), some parameters are varied differently from Table 2.

Parameters	Value with unit	Reference
Λ	10000 people per week	Assumed
β_1	0.0000001	Assumed
β_2	0.00000003	Assumed
p	0.02 week ⁻¹	Assumed
μ	0.0003 week ⁻¹	1/(65 × 48)
$1 - \delta_1$	0.75 (dimensionless)	Assumed that vaccine efficacy is 75% to native strain
$1 - \delta_2$	0.40 (dimensionless)	Assumed that vaccine efficacy is 40% to mutant strain
γ	1/32 week ⁻¹	Assumed that loss of immunity of vaccinated individuals after 32 weeks
a_1	1 week ⁻¹	Incubation (1 Week) [41]
a_2	1 week ⁻¹	Incubation (1 Week) [41]
α_1	1/2 week ⁻¹	Recovery (2 Weeks) [34]
α_2	1/2 week ⁻¹	Recovery (2 Weeks) [34]
d_1	0.0006 week ⁻¹	Assumed
d_2	0.0006 week ⁻¹	Assumed
$1 - \delta_3$	0.90 (dimensionless)	Assumed that recovered individuals have 90% immunity against mutant strain
ν_1	0.3 week ⁻¹	Assumed

Table 2: Numerical values of parameters.

The dynamics of system (1) are simulated using MATLAB 2018a. Figure 2(a) shows that for $R_0 = \max \{R_1, R_2\} = 0.9735 < 1$, DFE (D^0) is stable. Figure 2(b) represents that the mutant dominant equilibrium (D^2) is stable for $R_1 < 1$ and $R_2 > 1$. Further, Figure 3 shows that mutation rate (ν_1) can change the dynamics of positive equilibrium of system (1). Figure 3(a) represents that the positive equilibrium is stable. Figure 3(b) and (c) ensure that system (1) losses its stability around the positive equilibrium for high mutation rate and periodic solution occurs. Furthermore, Figure 3(d) shows that the positive equilibrium regains its stability for further higher mutation rate. This type of dynamics is called endemic bubble [45].




Figure 2: (a) The solution I_1 and I_2 of system (1) for the parametric values $\beta_1 = 0.0000000033$, $\beta_2 = 0.0000000017$, and others from Table 2. (b) The solution I_1 and I_2 of system (1) for $\beta_1 = 0.0000000033$, $\beta_2 = 0.00000003$, and other parametric values from Table 2.




Figure 3: (a) The solution I_1 and I_2 of system (1) for the parametric values in Table 2 and $\nu_1 = 0.3$. (b) The solution I_1 and I_2 of system (1) for $\nu_1 = 0.5$. (c) The solution I_1 and I_2 of system (1) for $\nu_1 = 0.7$. (d) The solution I_1 and I_2 of system (1) for $\nu_1 = 0.90$.

Furthermore, Figure 4 shows the positive equilibrium is locally asymptotically stable for small and larger enough values of ν_1 , but unstable for intermediate values of ν_1 . In this way, we get the bifurcation diagram in Figure 4, which we call an endemic bubble. As shown in the bifurcation diagram (Figure 4), for a lower range of values of ν_1 , both strains persist in the environment and system (1) is asymptotically stable. For a range of ν_1 , the periodic oscillations (limit cycle) will appear, but for higher values of ν_1 , system (1) regains its stability. Figure 5 illustrates the Hopf bifurcation diagram with respect to the parameter δ_3 . It shows that the system (1) is locally asymptotically stable for lower values of δ_3 and periodic solutions (Hopf bifurcation) appear for higher values of δ_3 .




Figure 4: Bifurcation diagram (endemic bubble) with respect to mutation rate (ν_1), other parametric values remain same as in Table 2. The blue color shows the upper limit of the limit cycle and red color shows the lower limit of the limit cycle.




Figure 5: Hopf bifurcation diagram with respect to δ_3 . We keep $\nu_1 = 0.4$ and other parametric values same as in Table 2. The blue color shows the upper limit of the limit cycle and red color shows the lower limit of the limit cycle.

7 Case study on COVID-19 data in India

Here we estimate the unknown parameters of the system (1) on the cumulative cases, and cumulative deaths of COVID-19 in India from March 1, 2021 to September 27, 2021 by using the MCMC algorithm [1, 29, 30]. We collect the data of cumulative cases and cumulative deaths of COVID-19 for March 1, 2021 to September 27, 2021 (31 weeks) from the WHO website [70]. By estimating the parameters, we estimate the mean values, standard deviation, and Geweke values of some parameters of the system (1). The cumulative cases can be given as

$$\frac{dC}{dt} = a_1 E_1 + a_2 E_2, \quad (21)$$

where $C(t)$ represents the cumulative cases, and the cumulative deaths can be given as

$$\frac{dD}{dt} = d_1 I_1 + d_2 I_2, \quad (22)$$

where $D(t)$ represents the cumulative deaths.

We use MCMC method for 20000 simulations to fit the Eq. (21) and estimate the parameters. Figure 6 represents a good fitting between the cumulative reported cases of COVID-19 and the model solution, well suggesting the epidemic trend in India. Some of the parameters of the system (1) are taken either from the literature or presumed based on publicly-available COVID-19 associated information. We assume parametric values of $a_1, a_2, \mu, \delta_1, \delta_2$, and δ_3 same as given in Table 2 and initial conditions given in Table 4.




Figure 6: Fitting result of the cumulative cases and cumulative deaths of COVID-19. (a) The blue solid boxes represent the actual reported cumulative cases and the orange curve represents the model output. (b) The blue solid boxes represent the actual reported cumulative deaths and the orange curve represents the model output. For the different colors in the Figure, refer to the web version of the paper.

By using MCMC method, we acquire the values of the parameters $\beta_1, \beta_2, \alpha_1, \alpha_2, \nu_1, d_1$, and d_2 with MCMC chain of the time evolution of the cumulative cases and comparison with the confirmed cases of COVID-19 in India. We compute the mean values, standard deviation, and Geweke values of these parameters (refer in Table 3).

Parameters	Mean value	Standard deviation	Geweke value	Reference
Λ	320000	-	-	Assumed
β_1	2.999e-07	5.3206e-13	0.99	MCMC
β_2	3.7618e-08	3.145e-14	0.95	MCMC
p	0.00002	-	-	Assumed
γ	0.01	-	-	Assumed
α_1	0.45	5.5791e-03	0.99	MCMC
α_2	0.2	1.6627e-03	0.98	MCMC
ν_1	0.03	3.265e-04	0.99	MCMC
d_1	0.007	5.347e-05	0.99	MCMC
d_2	0.00003	3.016e-7	0.99	MCMC

Table 3: Estimated values of parameters by MCMC method.

S(0)	V(0)	$E_1(0)$	$E_2(0)$	$I_1(0)$	$I_2(0)$	$R_1(0)$	$R_2(0)$
23×10^5	12256337	10×10^4	60×10^4	10×10^3	80×10^3	60×10^2	20×10^3

Table 4: Initial conditions for system (1) with respect to COVID-19 in India.

7.1 The effects of different efficacies of vaccine and mutation rate on cumulative cases and cumulative deaths over time

The system (1) is simulated to assess the population-level impact of the imperfect anti-COVID-19 vaccine in India. The population-level impact of the vaccine efficacy to both strains (native and mutant) on the burden of the pandemic is examined first of all. Firstly, we consider different values of the vaccine efficacy to the native strain. The system (1) is then simulated using the baseline parameter values in Table 2, 3, and different values of the vaccine efficacy ($1 - \delta_1$) to the native strain. The results obtained, depicted in Figure 7(a) show that, for the vaccine efficacy ($1 - \delta_1$) = 75% (assumed), 33,652,745 cumulative cases (the red curve) has reported by September 27, 2021. Predictions show that the cumulative cases would be recorded 40,350,000, by February 7, 2022 (31 weeks after September 27, 2021). The simulations, further, show a reduction with increasing values of the vaccine efficacy ($1 - \delta_1$) from its baseline value. In particular, if we consider the vaccine efficacy as ($1 - \delta_1$) = 90%, then 39,030,000 cumulative cases would be recorded by February 7, 2022, representing only 3.27% reduction. Figure 7(b) represents that, for the vaccine efficacy ($1 - \delta_2$) = 40% (assumed) to the mutant strain, 33,652,745 cumulative cases (the yellow curve) has reported by September 27, 2021. Simulations show that the cumulative cases would be recorded 41,520,000, by February 7, 2022. These simulations show that a reduction in the cumulative cases with increasing values of the vaccine efficacy ($1 - \delta_2$). Particularly, if we increase the vaccine efficacy ($1 - \delta_2$) = 75%, then 41,220,000 cumulative cases would be recorded by February 7, 2022. This represents 0.7% reduction in the cumulative cases. Furthermore, by increasing the vaccine efficacy ($1 - \delta_2$) = 90%, the cumulative cases would be decreased 0.9%.

The system (1) is simulated for different values of $1 - \delta_3$ (immunity against mutant strain). Figure 7(c) represents that, if recovered individuals by native strain have 90% immunity against mutant strain ($(1 - \delta_3) = 90\%$) (assumed) to the mutant strain, 33,652,745 cumulative cases (the blue curve) has reported by September 27, 2021. Simulations show that the cumulative cases would be recorded 40,350,000, by February 7, 2022. These simulations show that an increase in the cumulative cases with decreasing value of $1 - \delta_3$. Particularly, if we consider $(1 - \delta_3) = 75\%$, then 40,900,000 cumulative cases would be recorded by February 7, 2022. This represents 1.36% increase in the cumulative cases. If we consider $(1 - \delta_3) = 50\%$, then 42,920,000 cumulative cases would be recorded by February 7, 2022, representing 6.36% increase in the cumulative cases. Furthermore, if $(1 - \delta_3) = 25\%$, then 48,140,000 cumulative cases would be recorded by February 7, 2022, representing 19.3% increase in the cumulative cases.

Furthermore, simulations were also carried out to assess the impact of mutation rate on the disease dynamics of COVID-19. Figure 7(d) represents that, for the baseline value of the mutation rate ($\nu_1 = 0.03$), 33,652,745 cumulative cases (the red curve) has reported by September 27, 2021. Simulations show that the cumulative cases would be 40,370,000 by February 7, 2022. These simulations show an increase in the cumulative cases with increasing values of ν_1 . Particularly, an increase in $\nu_1 = 0.05$, then 40,380,000 cumulative cases would be recorded by February 7, 2022. This represents a 0.02% increase in the cumulative cases. Furthermore, an increase in $\nu_1 = 0.09$, then 40,480,000 cumulative cases would be recorded by February 7, 2022, representing 0.27% increase in the cumulative cases.




Figure 7: Assessment of the impacts of different parameters on the cumulative cases of COVID-19 in India. Simulations of the system (1) shows the cumulative cases of COVID-19 in India, as a function of time, (a) for different values of vaccine efficacy to native strain ($1 - \delta_1$). (b) for different values of vaccine efficacy to mutant ($1 - \delta_2$). (c) for different values of immunity against mutant strain ($1 - \delta_3$). (d) for different values of mutation rate (ν_1). The baseline parameter values are used from Tables 2 and 3.

To examine the dependence of the end time (February 7, 2022) of the epidemic on the vaccine efficacies to both native and mutant strains, i.e. ($1 - \delta_1$), ($1 - \delta_2$), mutation rate (ν_1), and immunity against mutant strain ($1 - \delta_3$), we sketch the contour plots of the total number of the cumulative cases of COVID-19, with respect to ($1 - \delta_1$) and ($1 - \delta_2$) in Figure 8(a); ($1 - \delta_3$) and ν_1 in Figure 8(b); ($1 - \delta_2$) and ν_1 in Figure 8(c); ($1 - \delta_2$) and ($1 - \delta_3$) in Figure 8(d); respectively. In order to assess the combined effect of the parameters, the other parameters remain fixed when we vary two parameters. The results indicate that increasing the vaccine efficacies ($1 - \delta_1$) and ($1 - \delta_2$), the cumulative cases would be reduced (Figure 8(a)). It can also be observed that the vaccine efficacy to the native strain ($1 - \delta_1$) is more influential than the vaccine efficacy to the mutant strain ($1 - \delta_2$), in controlling the total number of cases. In the same way, the result in Figure 8(b) shows that the cumulative number of cases would be reduced for the higher immunity against mutant strain ($1 - \delta_3$) and lower value of mutation rate (ν_1). The result also shows that cumulative cases would be higher for the lower value of ($1 - \delta_3$) and lower value of (ν_1). The result in Figure 8(c) shows that the cumulative number of cases would be reduced for the higher vaccine efficacy to the mutant strain ($1 - \delta_2$) and lower value of mutation rate (ν_1). The result also shows that cumulative cases would be higher for the lower value of ($1 - \delta_2$) and higher value of (ν_1). Figure 8(d) represents that the cumulative number of cases would be reduced only for higher immunity against mutant strain ($1 - \delta_3$). This result makes it wonder that cumulative cases would be higher even for the higher value of the vaccine efficacy to the mutant strain ($1 - \delta_2$) if there is a low value of immunity against

mutant strain. This means there may exist an appropriate combination of these parameters to ensure fewer confirmed cases. Thus, it would be interesting to consider an optimal strategy for supplying vaccines to minimize the cumulative number of cases.




Figure 8: Contour plots of the cumulative cases, as a function of different parameters: (a) as a function of vaccine efficacy ($1 - \delta_1$) to native strain and vaccine efficacy ($1 - \delta_2$) to mutant strain; (b) as a function of immunity against mutant strain ($1 - \delta_3$) and mutation rate (ν_1); (c) as a function of vaccine efficacy ($1 - \delta_2$) to mutant strain and mutation rate (ν_1); (d) as a function of vaccine efficacy ($1 - \delta_2$) to mutant strain and immunity against mutant strain ($1 - \delta_3$). The baseline parameter values are used from Tables 2 and 3.

Furthermore, the impact of vaccine efficacies on cumulative deaths is examined. The result in Figure 9(a) shows that for the vaccine efficacy ($1 - \delta_1$) = 75% (assumed), 446918 cumulative deaths (red curve) has reported by September 27, 2021. Predictions show that the cumulative deaths would be recorded at 534431 by February 7, 2022 (31 weeks after September 27, 2021). The simulations further show a reduction with increasing values of the vaccine efficacy ($1 - \delta_1$) from its baseline value. In particular, if we consider the vaccine efficacy as ($1 - \delta_1$) = 90%, then 506562 cumulative deaths would be recorded by February 7, 2022, representing only a 5.2% reduction. Figure 9(b) represents that, for the vaccine efficacy ($1 - \delta_2$) = 40% (assumed) to the mutant strain, 446918 cumulative deaths (yellow curve) has reported by September 27, 2021. Simulations show that the cumulative deaths would be recorded at 543330 by February 7, 2022. Further simulations show a reduction in the cumulative deaths with increasing values of the vaccine efficacy ($1 - \delta_2$). Particularly, if we increase the vaccine efficacy ($1 - \delta_2$) = 75%, then 537342 cumulative deaths would be recorded by February 7, 2022, representing a 1.1% reduction in the cumulative deaths. Furthermore, by increasing the vaccine efficacy ($1 - \delta_2$) = 90%, 529420 cumulative deaths would be recorded, representing 2.5% reduction.




Figure 9: Assessment of the impacts of different parameters on the cumulative deaths of COVID-19 in India. Simulations of the system (1) show the cumulative deaths of COVID-19 in India, as a function of time, (a) for different values of vaccine efficacy to native strain ($1 - \delta_1$); (b) for different values of vaccine efficacy to mutant ($1 - \delta_2$). The baseline parameter values are used from Tables 2 and 3.

7.2 Impact of mutation rate on the dynamics of strains and infected population over time

The impact of mutation rate (ν_1) has been analyzed on the dynamics of strains and total infected population for COVID-19. We can explicitly explore how the numbers of infected individuals I_1 and I_2 depend on the mutation parameter ν_1 . As shown in the bifurcation diagram (Figure 10), for the range of mutation rate, $0 < \nu_1 \leq 1.7$, both strains persist in the environment, and disease is asymptotically stable. For $1.7 < \nu_1 \leq 3.3$, the periodic oscillations (limit cycle) will appear, i.e. the disease outbreak will occur repeatedly. However, for a higher value of ν_1 , i.e. for $\nu_1 > 3.3$, the periodic solutions disappear and the disease again becomes stable. This dynamical phenomenon has been illustrated in Figure 11, for the values $\nu_1 = 1, 2.5$ and 3.53 . Furthermore, we have plotted the total infected population ($E_1 + E_2 + I_1 + I_2$) over time for different values of ν_1 in Figure 12. This result gives a wondering dynamics over a long time. We can easily observe that if the mutation rate (ν_1) increases from 0.01 to 0.09, then the infected population persists at a lower level (blue and red curves). In addition, if the value of ν_1 is increased to 2.5, then the total infected population oscillates over time (orange curve). If the value of ν_1 is further increased to 3.5, then the infected population persists at a much lower level (purple curve) over long time.




Figure 10: Bifurcation diagram (endemic bubble) with respect to mutation rate (ν_1) for the fitted values of parameters given in Table 3. The blue color shows the upper limit of the limit cycle and red color shows the lower limit of the cycle.




Figure 11: Impact of mutation rate on the infected populations I_1 and I_2 . (a) The asymptotically stable solutions I_1 and I_2 of system (1) for the parametric values in Table 3 and $\nu_1 = 1$. (b) The periodic solutions I_1 and I_2 of system (1) for $\nu_1 = 2.5$. (c) The asymptotically stable solutions I_1 and I_2 of system (1) for $\nu_1 = 3.53$.




Figure 12: Variation of the total infected population with respect to different mutation rate (ν_1).

8 Sensitivity analysis

Our ultimate goal in developing a mathematical model of two strains with imperfect vaccine and mutation is to find the role of different parameters to control the disease. From the viewpoints of biological significance, R_0 plays a vital role in determining the severity (burden of disease), outcome and process of the infection. This section investigates how a percentage change in key parameters in the model affects (change) the basic reproduction number. In the system (1), the most critical parameter to reduce is the basic reproduction numbers of different strains. If the basic reproduction number is brought below one, the disease infection will be eliminated. Even if the basic reproduction number cannot be brought below one, sensitivity analysis may help to determine which parameter, if acted upon, will bring the largest reduction in the basic reproduction numbers. Sensitivity indices measure the percentage change of a key quantity, such as the basic reproduction number, in response to a percentage change of a parameter in that quantity. Sensitivity analysis is carried out on each parameter, which is utilized to recognize and check parameters responsible for impacting the basic reproductive number. The normalized sensitivity indices, also called elasticity of the quantity Q with respect to the parameter p , is defined as follows [69]:

$$\epsilon_p^Q = \frac{\partial Q}{\partial p} \frac{p}{Q}. \quad (23)$$

Elasticities can be positive or negative. A positive sign says that quantity Q increases with the increase in parameter p , while a negative sign says that quantity Q decreases with the increase of parameter p .

Parameters	Values of elasticities of R_1	Values of elasticities of R_2
Λ	1	1
β_1	1	-
β_2	-	1
a_1	0.00029	-
a_2	-	0.00029
γ	0.0014	0.00075
μ	-1	-1
p	-0.0014	-0.00077
δ_1	0.00048	-
δ_2	-	0.00116
d_1	-0.0143	-
d_2	-	-0.00015
α_1	-0.9234	-
α_2	-	-0.998
ν_1	-0.0615	-

Table 5: List of elasticities of R_1 and R_2 .

We compute the elasticity indices for the basic reproduction numbers R_1 and R_2 given in Table 5. In Table 5, the parameters with positive sensitivity indices are those parameters that have a great influence on the development of the disease in the community if their values are increasing. This is because the basic reproduction number increases as their value increases; that is, the average number of secondary cases of infection increases in the community. Also, all the parameters in which their indices are negative can curtail the infection in the community as their values increase while the others are left constant. As their values increase, the basic reproduction number decreases, which reduces the endemicity of the disease in the community.

It is evident from the values of elasticities that the reproduction number will experience the highest impact with change to recruitment rate (Λ), transmission rates ((β_1) and (β_2)), and natural death rate (μ). In general, acting on any parameters produces a similar change in the reproduction number. For the basic reproduction number R_0 , the elasticities concerning the parameters Λ, β_1 , and β_2 , are fairly similar, which means these parameters have the same impact on R_0 .

We also perform sensitivity analysis using the methodology of Latin Hypercube Sampling (LHS) and partial rank correlation coefficients (PRCCs) [49] to investigate the dependence of R_0 on the different parameters. From Figure 13, we observe that recruitment rate (Λ), transmission rates (β_1, β_2), natural death rate (μ), and recovery rates (α_1, α_2) are the most sensitive parameters for R_0 . To generate the LHS matrices, we assume that all the model parameters are uniformly distributed. Then using the baseline values from Tables 2 and 3, a total of 1000 simulations per LHS run are carried out.

We also examine the impact of sensitivities of the parameters on the population size of cumulative cases (C) and cumulative deaths (D). From Figure 14, we observe that $\beta_1, a_1, \beta_2, a_2$ are the most sensitive parameters to the cumulative cases, which means that the value of these parameters increases the cumulative cases will increase. This result implies that we should control these parameters to reduce the cumulative cases. From Figure 15, we observe that $\beta_1, a_1, d_1, \alpha_1$ are the most sensitive parameters to the cumulative deaths and β_1, a_1, d_1 has positive sensitivity and α_1 has negative sensitivity, indicating that we should control the parameters β_1, a_1, d_1 and promote α_1 to reduce the cumulative deaths.




Figure 13: PRCC sensitivity on R_0 .




Figure 14: PRCC sensitivity on cumulative cases (C).




Figure 15: PRCC sensitivity on cumulative deaths (D).

9 Discussion

The novel coronavirus has rapidly emerged as a disease COVID-19 and evolved as pandemics worldwide. The emergence of new variants of SARS-CoV-2 could complicate mitigation efforts. Reducing the transmission of the novel coronavirus pandemic has been the massive responsibility of the intellects of every public health agencies, Govt. officials, and millions of populations

worldwide. According to the World Health Organization (WHO) [71], over 26 crore populations are infected with the COVID-19 as of December 4, 2021. Now, the Govt. of different countries are trying to give safeguards to the populations via vaccination. Since every vaccine is imperfect to the disease and the virus mutates over time, mathematical models may help understand the dynamics of transmission and control of the novel coronavirus.

Taking care of the pandemic scenario, we proposed and analyzed an SEIR type multi-strain mathematical model with imperfect vaccine and mutation (1). We also assumed that recovered individuals of native strain could become infected by the mutant strain, but they have some immunity against the mutant strain, and it has been modeled by multiplying a reduction coefficient to the transmission rate. The model we developed takes the form of a deterministic system of nonlinear differential equations. The model is rigorously analyzed to gain insight into its dynamical features. Theoretical and numerical analysis of the proposed system (1) have been carried out using stability theory. Positivity and boundedness of the solutions of system (1) have been studied, and the system (1) is well-posed. We found that the DFE (D^0) is globally stable when $R_0 < 1$ in the presence of an imperfect vaccine, i.e., the native and mutant strains will be eliminated in the community whenever $R_0 < 1$. In other words, the imperfect vaccine against COVID-19 can lead to the eradication of the pandemic if it can bring (or maintain) R_0 to a value less than unity. Further, we analyzed the existence and stability of the mutant dominant equilibrium (D^2) by constructing a suitable Lyapunov function. Global stability of coexistence (positive) equilibrium of both native and mutant strains has been investigated for the case $\nu_1 = 0$ and $\delta_3 = 0$, by constructing a suitable Lyapunov function. This result implies that if the mutation rate is zero and recovered individuals from native strain have 100% immunity against mutant strain, the disease persists in the environment when $R_0 > 1$. Moreover, we investigated that system (1) undergoes a Hopf bifurcation. The transcritical bifurcation was also investigated for system (1) by using center manifold theory. By numerical simulation, we discovered that system (1) exhibits an interesting dynamics called an endemic bubble, which means the system losses its stability when the mutation rate (ν_1) is larger, and oscillations occur, and further larger value of ν_1 , the system regains its stability (refer the Figure 4). The occurrence of Hopf bifurcation was also ensured by varying the parameter δ_3 (Figure 5), which implies that the disease will appear repeatedly for the higher value of δ_3 . We also computed an expression for herd immunity and a threshold value for the vaccination rate that suggests disease control implications. The mentioned necessary herd immunity (induced by vaccination) percentage may not be realistically achievable. Indeed, Dr. Anthony Fauci, a member of the US Presidential Task Force on COVID-19, said on June 29, 2020, that an imaginary anti-COVID-19 vaccine might not attain the requisite high immunity in the US if many people deny getting it [11]. One way to get around this requirement for high vaccine coverage to attain high immunity is to merge the vaccination program with other anti-COVID-19 intervention strategies, such as social distancing, the use of face masks in public, etc.

Furthermore, we parameterized the proposed mathematical model using the data of the COVID-19 pandemic in India, for assessing the potential community-wide impact of an imperfect vaccine against COVID-19 and mutation of the virus. Using the data of cumulative confirmed cases and cumulative deaths of COVID-19 in India from March 1, 2021 to September 27, 2021. By employing the MCMC method to fit the model (1) with the cumulative cases and cumulative deaths, the mean values, the standard deviation, and Geweke values of the unknown parameters were estimated.

We carried out numerical simulations to measure the population-level impact of the vaccine's efficacies. The results exhibited that the COVID-19 burden (as measured in terms of cumulative cases and cumulative deaths) decreases with increasing vaccine efficacies, as expected. We investigated how the cumulative number of cases varies with different values of vaccine efficacies to different strains, mutation rate, and immunity against the mutant strain in India. Our

analysis showed what would happen if the vaccine efficacy to native strain was increased from its baseline value, as shown in Figure 7(a). The results showed that if the vaccine efficacy $(1 - \delta_1) = 90\%$ was increased by its baseline value $(1 - \delta_1) = 75\%$, then the cumulative cases would be decreased by 3.27% by February 7, 2022. Figure 7(b) demonstrated that if the vaccine efficacy to mutant strain increased as $(1 - \delta_2) = 75\%$ from its baseline value $(1 - \delta_2) = 40\%$, then cumulative cases would be decreased by 0.7%. We also assessed the impact of immunity against mutant strain $(1 - \delta_3)$. We analyzed that if the value of $(1 - \delta_3)$ is considered as 25%, which is decreased from its baseline value $(1 - \delta_3) = 90\%$, then the cumulative cases would be increased by 19.3% by February 7, 2022, shown in 7(c). We also analyzed the impact of mutation rate on cumulative cases, which represents the increase in cumulative cases with increasing mutation rate, showing in 7(d). Our analysis also showed the combined impact of vaccine efficacies to both strains, which were increased to 20%, 40%, 60%, 80%, respectively, as shown in Figure 8(a). The result demonstrated that increasing the vaccine efficacy to the native strain is more influential in reducing the cumulative number of cases than the efficacy to mutant strain. We have shown in the contour plot (Figure 8(b)) that there would be higher cumulative cases for the lower immunity against mutant strain even for the lower value of the mutation rate. There will be fewer cumulative cases if immunity against mutant strain is high. The contour plot (Figure 8(c)) exhibited that cumulative cases would be high for the higher mutation rate and lower vaccine efficacy to the mutant strain. This implies that there is a need to increase in the vaccine efficacy $(1 - \delta_2)$ to decrease the cumulative cases of COVID-19 in the presence of the mutation. The cumulative number of deaths has also been varied with different values of vaccine's efficacies to different strains in Figure 9. The results in Figure 9(a) showed that if the vaccine efficacy $(1 - \delta_1) = 90\%$ was increased by its baseline value $(1 - \delta_1) = 75\%$, then the cumulative deaths would be decreased by 5.2% by February 7, 2022. Figure 9(b) demonstrated that if the vaccine efficacy to mutant strain increased as $(1 - \delta_2) = 75\%$ from its baseline value $(1 - \delta_2) = 40\%$, then cumulative deaths would be decreased by 1.1%.

The endemic bubble phenomenon has been verified for COVID-19 by plotting the bifurcation diagram and periodic solutions for the fitted values from Table 3 in Figures 10 and 11, respectively. These results imply that for a range of values of mutation rate (ν_1), the COVID-19 outbreak will occur repeatedly. However, for the lower and higher enough values of ν_1 , the disease remains stable in the environment. These dynamics represent a worse scenario for the mutation of the virus in the sense of the occurrence of periodic solutions. Furthermore, the total infected population has also been plotted for different values of mutation rate ν_1 and a wondering dynamics has been observed. This result shows that for a high rate of mutation, the total infected population would be stable at a lower level over a long time. However, oscillation occurs for an intermediate range of mutation rate, implying that mutation may be worse in the sense of oscillation but better in the sense of stability at a lower infection level over a long time.

Furthermore, sensitivity analysis was performed to reveal the relative significance of the key epidemiological parameters of the system (1), which are $\Lambda, \beta_1, \beta_2, \alpha_1, \alpha_2$, because these parameters should be given priority to effectively control the disease. The PRCCs of the reproduction number (Figure 13) showed that reducing $\Lambda, \beta_1, \beta_2$, which may be realized by strong control measures, such as lockdown, using face mask, travel restriction, isolation of infected individuals, contact tracing, can significantly reduce R_0 and thus lower the transmission risk of COVID-19. The PRCCs of the cumulative cases and deaths suggest that the parameters $\beta_1, \alpha_1, \beta_2$, and α_2 should be controlled in order to reduce the cumulative cases, and β_1, α_1 , and d_1 should be controlled in order to reduce the cumulative deaths.

We have to point out that the results in contour plots revealed an interesting problem, i.e., there may exist an optimal strategy of supplementing the vaccine with different efficacies, in order to ensure that the fewer cumulative cases and cumulative deaths, and that the expenditure

is economical, a topic for our future work. For preserving public health, it must be focused on how the facility of medical resources availability affects the pandemic of COVID-19, which could be included in our model as future work. Formulating and analyzing the model with other non-pharmaceutical interventions [73] with vaccination will be more helpful to control the spread of multi-strain disease. For instance, Iboi et al. [33] proposed a dynamical model to assess the impact of vaccine strategy with other public health intervention strategies; in particular, the authors assessed the impact of vaccine efficacy combined with mask efficacy concerning COVID-19 in the US. Their results confirmed that the elimination of COVID-19 is more feasible if the vaccine program is combined with other interventions. We focused on the situation in India, but the model can be extended to describe the efficacies of vaccines to different strains with mutation rates and developed immunity against mutant strains in other countries.

References

- [1] Ahmed SE (2008) Markov chain monte carlo: Stochastic simulation for bayesian inference. <https://doi.org/10.1198/tech.2008.s542>.
- [2] Alexander ME, Bowman C, Moghadas SM, Summers R, Gumel AB, Sahai BM (2004) A vaccination model for transmission dynamics of influenza. *SIAM Journal on Applied Dynamical Systems* 3(4):503-524. <https://doi.org/10.1137/030600370>.
- [3] Anderson RM (1992) The concept of herd immunity and the design of community-based immunization programmes. *Vaccine* 10:928e935. [https://doi.org/10.1016/0264-410X\(92\)90327-G](https://doi.org/10.1016/0264-410X(92)90327-G).
- [4] Anderson RM, May RM (1985) Vaccination and herd immunity to infectious diseases. *Nature* 318:323e329. <https://doi.org/10.1038/318323a0>.
- [5] Arino J, McCluskey CC, van den Driessche P (2003) Global results for an epidemic model with vaccination that exhibits backward bifurcation. *SIAM Journal on Applied Mathematics* 64(1):260-276. <https://doi.org/10.1137/S0036139902413829>.
- [6] Arruda EF, Pastore DH, Dias CM, Das SS (2021) Modelling and Optimal Control of Multi Strain Epidemics, with Application to COVID-19. arXiv preprint 2101:08137. [10.1371/journal.pone.0257512](https://doi.org/10.1371/journal.pone.0257512).
- [7] Bajiya VP, Bugalia S, Tripathi JP (2020) Mathematical modeling of COVID-19: impact of non-pharmaceutical interventions in India. *Chaos: An Interdisciplinary Journal of Non-linear Science* 30(11):113143. <https://doi.org/10.1063/5.0021353>.
- [8] Bugalia S, Bajiya VP, Tripathi JP, Li MT, Sun GQ (2020) Mathematical modeling of COVID-19 transmission: the roles of intervention strategies and lockdown. *Mathematical Biosciences and Engineering* 17(5):5961-5986. [10.3934/mbe.2020318](https://doi.org/10.3934/mbe.2020318).
- [9] Bugalia S, Tripathi JP, Wang H (2021) Mathematical modeling of intervention and low medical resource availability with delays: Applications to COVID-19 outbreaks in Spain and Italy. *Mathematical Biosciences and Engineering* 18(5):5865-5920. [10.3934/mbe.2021295](https://doi.org/10.3934/mbe.2021295).
- [10] Bussiness Insider (2021) <https://tinyurl.com/6q3g47b8>. Accessed 2 November 2021.

- [11] Cable News Network (2020) Fauci says covid-19 vaccine may not get us to herd immunity if too many people refuse to get it, CNN. <https://edition.cnn.com/2020/06/28/health/fauci-coronavirus-vaccine-contact-tracing-aspen/index.html>. Accessed 10 September 2021.
- [12] Cai L, Xiang J, Li X, Lashari AA (2012) A two-strain epidemic model with mutant strain and vaccination. *Journal of Applied Mathematics and Computing* 40(1):125-142. <https://doi.org/10.1007/s12190-012-0580-x>.
- [13] Cai LM, Li Z, Song X (2018) Global analysis of an epidemic model with vaccination. *Journal of Applied Mathematics and Computing* 57(1):605-628. <https://doi.org/10.1007/s12190-017-1124-1>.
- [14] Castillo-Chavez C, Blower S, Van den Driessche P, Kirschner D, Yakubu AA, editors (2002) *Mathematical approaches for emerging and reemerging infectious diseases: models, methods, and theory*. Springer Science & Business Media.
- [15] Castillo-Chavez C, Feng Z, Huang W (2002) On the computation of R_0 and its role in global stability. *IMA Volumes in Mathematics and Its Applications* 125:229-250.
- [16] Castillo-Chavez C, Song B (2004) Dynamical models of tuberculosis and their applications. *Mathematical Biosciences & Engineering* 1(2):361. 10.3934/mbe.2004.1.361.
- [17] Centers for Disease Control and Prevention (CDC) (2021). <https://www.cdc.gov/coronavirus/2019-ncov/variants/variant.html>. Accessed 13 October 2021.
- [18] Centers for Disease Control and Prevention (CDC) (2021). <https://www.cdc.gov/coronavirus/2019-ncov/your-health/reinfection.html>. Accessed 13 October 2021.
- [19] Deng X, Garcia-Knight MA, Khalid MM, Servellita V, Wang C, Morris MK, Sotomayor-González A, Glasner DR, Reyes KR, Gliwa AS, Reddy NP (2021) Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant. *Cell*. <https://doi.org/10.1016/j.cell.2021.04.025>.
- [20] Diekmann O, Heesterbeek JA, Roberts MG (2010) The construction of next-generation matrices for compartmental epidemic models. *Journal of the Royal Society Interface* 7(47):873-885. <https://doi.org/10.1098/rsif.2009.0386>.
- [21] Elbasha EH, Gumel AB (2021) Vaccination and herd immunity thresholds in heterogeneous populations. *Journal of Mathematical Biology* 83(6-7). <https://doi.org/10.1007/s00285-021-01686-z>.
- [22] Eron JJ, Vernazza PL, Johnston DM, Seillier-Moiseiwitsch F, Alcorn TM, Fiscus SA, Cohen MS (1998) Resistance of HIV-1 to antiretroviral agents in blood and seminal plasma: implications for transmission. *Aids* 12(15):F181-F189.
- [23] Friedman TL, Is Sweden doing it right? *New York Times*, <https://www.nytimes.com/2020/04/28/opinion/coronavirus-sweden.html>. Accessed 3 October 2021.
- [24] Fudolig M, Howard R (2020) The local stability of a modified multi-strain SIR model for emerging viral strains. *PloS One* 15(12):e0243408. <https://doi.org/10.1371/journal.pone.0243408>.
- [25] Gonzalez-Parra G, Martínez-Rodríguez D, Villanueva-Micó RJ (2021) Impact of a new SARS-CoV-2 variant on the population: A mathematical modeling approach. *Mathematical and Computational Applications* 26(2):25. <https://doi.org/10.3390/mca26020025>.

- [26] Gukenheimer J, Holmes P (1983) Nonlinear oscillations, Dynamical Systems, and Bifurcation of Vector Fields. Springer-Verlag NY.
- [27] Gumel AB, McCluskey CC, Watmough J (2006) An SVEIR model for assessing potential impact of an imperfect anti-SARS vaccine. *Mathematical Biosciences & Engineering* 3(3):485. [10.3934/mbe.2006.3.485](https://doi.org/10.3934/mbe.2006.3.485).
- [28] Gupta S, Ferguson NM, Anderson RM (1997) Vaccination and the population structure of antigenically diverse pathogens that exchange genetic material. *Proceedings of the Royal Society of London. Series B: Biological Sciences* 264(1387):1435-1443. <https://doi.org/10.1098/rspb.1997.0200>.
- [29] Haario H, Laine M, Mira A, Saksman E (2006) DRAM: efficient adaptive MCMC. *Statistics and computing* 16(4):339-354. <https://doi.org/10.1007/s11222-006-9438-0>.
- [30] Haario H, Saksman E, Tamminen J (2001) An adaptive Metropolis algorithm. *Bernoulli* 7(2):223-242. <https://doi.org/10.2307/3318737>.
- [31] Health, The Sciences, <https://science.thewire.in/the-sciences/covid-19-reinfection-hong-kong-man-immunity/>. Accessed 10 November 2021.
- [32] Hethcote HW (2000) The mathematics of infectious diseases. *SIAM review Society for Industrial and Applied Mathematics* 42(4):599-653. <https://doi.org/10.1137/S0036144500371907>.
- [33] Iboi EA, Ngonghala CN, Gumel AB (2020) Will an imperfect vaccine curtail the COVID-19 pandemic in the US? *Infectious Disease Modelling* 5:510-524. <https://doi.org/10.1016/j.idm.2020.07.006>.
- [34] Iboi EA, Sharomi OO, Ngonghala CN, Gumel AB (2020) Mathematical modeling and analysis of COVID-19 pandemic in Nigeria. *Mathematical Biosciences and Engineering* 17(6):7192-7220. [10.3934/mbe.2020369](https://doi.org/10.3934/mbe.2020369).
- [35] Iwami S, Takeuchi Y, Liu X (2007) Avian-human influenza epidemic model. *Mathematical Biosciences* 207(1):1-25. <https://doi.org/10.1016/j.mbs.2006.08.001>.
- [36] Johns Hopkins Medicine, <https://www.hopkinsmedicine.org/health/conditions-and-diseases/coronavirus/a-new-strain-of-coronavirus-what-you-should-know>. Accessed 17 September 2021.
- [37] Kermack WO, McKendrick AG (1927) A contribution to the mathematical theory of epidemics. *Proceedings of the Royal Society of London, Series A, Containing papers of a mathematical and physical character* 115(772):700-721. <https://doi.org/10.1098/rspa.1927.0118>.
- [38] Khyar O, Allali K (2020) Global dynamics of a multi-strain SEIR epidemic model with general incidence rates: application to COVID-19 pandemic. *Nonlinear Dynamics* 102(1):489-509. <https://doi.org/10.1007/s11071-020-05929-4>.
- [39] Korber B, Fischer WM, Gnanakaran S, Yoon H, Theiler J, Abfalterer W, Hengartner N, Giorgi EE, Bhattacharya T, Foley B, Hastie KM (2020) Tracking changes in SARS-CoV-2 Spike: evidence that D614G increases infectivity of the COVID-19 virus. *Cell* 182(4):812-827. <https://doi.org/10.1016/j.cell.2020.06.043>.
- [40] LaSalle JP (1976) The stability of dynamical systems. *Society for Industrial and Applied Mathematics*.

- [41] Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, Azman AS, Reich NG, Lessler J (2020) The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. *Annals of internal medicine* 172(9):577-582. <https://doi.org/10.7326/M20-0504>.
- [42] Lemieux JE, Li JZ (2021) Uncovering Ways that Emerging SARS-CoV-2 Lineages May Increase Transmissibility. *The Journal of Infectious Diseases* 223(10):1663–1665. <https://doi.org/10.1093/infdis/jiab083>.
- [43] Li J, Zhou Y, Ma Z, Hyman JM (2004) Epidemiological models for mutating pathogens. *SIAM Journal on Applied Mathematics* 65(1):1-23. <https://doi.org/10.1137/S0036139903430185>.
- [44] Liu L, Ren X, Liu X (2018) Dynamical behaviors of an influenza epidemic model with virus mutation. *Journal of Biological Systems* 26(03):455-472. <https://doi.org/10.1142/S0218339018500201>.
- [45] Liu M, Liz E, Rost G (2015) Endemic bubbles generated by delayed behavioral response: global stability and bifurcation switches in an SIS model. *SIAM Journal on Applied Mathematics* 75(1):75-91. <https://doi.org/10.1137/140972652>.
- [46] Liu WM (1994) Criterion of Hopf bifurcations without using eigenvalues. *Journal of Mathematical Analysis and Applications* 182(1):250-256. <https://doi.org/10.1006/jmaa.1994.1079>.
- [47] Liu X, Takeuchi Y, Iwami S (2008) SVIR epidemic models with vaccination strategies. *Journal of Theoretical Biology* 253(1):1-11. <https://doi.org/10.1016/j.jtbi.2007.10.014>.
- [48] MacIntyre CR, Costantino V, Trent MJ (2021) Modelling of COVID-19 vaccination strategies and herd immunity, in scenarios of limited and full vaccine supply in NSW, Australia. *Vaccine*. <https://doi.org/10.1016/j.vaccine.2021.04.042>.
- [49] Marino S, Hogue IB, Ray CJ, Kirschner DE (2008) A methodology for performing global uncertainty and sensitivity analysis in systems biology. *Journal of Theoretical Biology* 254(1):178-196. <https://doi.org/10.1016/j.jtbi.2008.04.011>.
- [50] Martcheva M (2015) An introduction to mathematical epidemiology. New York: Springer. <https://doi.org/10.1007/978-1-4899-7612-3>.
- [51] Martcheva M, Iannelli M, Li XZ (2007) Subthreshold coexistence of strains: the impact of vaccination and mutation. *Mathematical Biosciences and Engineering* 4(2):287. [10.3934/mbe.2007.4.287](https://doi.org/10.3934/mbe.2007.4.287).
- [52] May RM, Nowak MA (1995) Coinfection and the evolution of parasite virulence. *Proceedings of the Royal Society of London. Series B, Biological Sciences* 261(1361):209-215. <https://doi.org/10.1098/rspb.1995.0138>.
- [53] May RM, Nowak MA (1994) Superinfection, metapopulation dynamics, and the evolution of diversity. *Journal of Theoretical Biology* 170(1):95-114. <https://doi.org/10.1006/jtbi.1994.1171>.
- [54] McLean AR (1995) Vaccination, evolution and changes in the efficacy of vaccines: a theoretical framework. *Proceedings of the Royal Society of London. Series B, Biological Sciences* 261(1362):389-393. <https://doi.org/10.1098/rspb.1995.0164>.

- [55] Ministry of Health and Family Welfare, Government of India. https://www.mohfw.gov.in/covid_vaccination/vaccination/faqs.html#what-to-expect-before-vaccination-2. Accessed 16 October 2021.
- [56] Nature news, <https://www.nature.com/articles/d41586-021-01059-y>. Accessed 18 October 2021.
- [57] Olhiero P, Torreele E, Vaillant M (2021) COVID-19 vaccine efficacy and effectiveness—the elephant (not) in the room. *The Lancet Microbe*. [https://doi.org/10.1016/S2666-5247\(21\)00069-0](https://doi.org/10.1016/S2666-5247(21)00069-0).
- [58] Palese P, Young JF (1982) Variation of influenza A, B, and C viruses. *Science* 215(4539):1468-1474. [10.1126/science.7038875](https://doi.org/10.1126/science.7038875).
- [59] Parton R, Hall E, Wardlaw AC (1994) Responses to *Bordetella pertussis* mutant strains and to vaccination in the coughing rat model of pertussis. *Journal of Medical Microbiology* 40(5):307-312. <https://doi.org/10.1099/00222615-40-5-307>.
- [60] Porco TC, Blower SM (1998) Designing HIV vaccination policies: subtypes and cross-immunity. *Interfaces* 28(3):167-190. <https://doi.org/10.1287/inte.28.3.167>.
- [61] Porco TC, Blower SM (2000) HIV vaccines: the effect of the mode of action on the coexistence of HIV subtypes. *Mathematical Population Studies* 8(2):205-229. <https://doi.org/10.1080/08898480009525481>.
- [62] Public Health England (2021) investigation-of-novel-sars-cov-2-variant-variant-of-concern-20201201. <https://www.gov.uk/government/publications/investigation-of-novel-sars-cov-2-variant-variant-of-concern-20201201>. Accessed 27 September 2021.
- [63] Rahimi F, Abadi AT (2021) Implications of the Emergence of a New Variant of SARS-CoV-2, VUI-202012/01. *Archives of Medical Research* 52(5):569–571. <https://doi.org/10.1016/j.arcmed.2021.01.001>.
- [64] Sansonetti PJ, Arondel J (1989) Construction and evaluation of a double mutant of *Shigella flexneri* as a candidate for oral vaccination against shigellosis. *Vaccine* 7(5):443-450. [https://doi.org/10.1016/0264-410X\(89\)90160-6](https://doi.org/10.1016/0264-410X(89)90160-6).
- [65] Sato S, Suzuki K, Akahane Y, Akamatsu K, Akiyama K, Yunomura K, Tsuda F, Tanaka T, Okamoto H, Miyakawa Y, Mayumi M (1995) Hepatitis B virus strains with mutations in the core promoter in patients with fulminant hepatitis. *Annals of Internal Medicine* 122(4):241-248. <https://doi.org/10.7326/0003-4819-122-4-199502150-00001>.
- [66] Scherer A, McLean A (2002) Mathematical models of vaccination. *British Medical Bulletin* 62(1):187-199. <https://doi.org/10.1093/bmb/62.1.187>.
- [67] Shastri J, Parikh S, Aggarwal V, Agrawal S, Chatterjee N, Shah R, Devi P, Mehta P, Pandey R (2021) Severe SARS-CoV-2 breakthrough reinfection with Delta variant after recovery from breakthrough infection by Alpha variant in a fully vaccinated health worker. *Frontiers in Medicine* 1379. <https://doi.org/10.3389/fmed.2021.737007>.
- [68] Van den Driessche P, Watmough J (2002) Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission. *Mathematical Biosciences* 180(1-2):29-48. [https://doi.org/10.1016/S0025-5564\(02\)00108-6](https://doi.org/10.1016/S0025-5564(02)00108-6).

- [69] Martcheva M (2014) Avian flu: modeling and implications for control. *Journal of Biological Systems* 22(01):151-75. <https://doi.org/10.1142/S0218339014500090>.
- [70] World Health Organization, <https://covid19.who.int/region/searo/country/in>. Accessed 29 October 2021.
- [71] World Health Organization, <https://covid19.who.int/>. Accessed 29 October 2021.
- [72] World Health Organization, WHO advisory committee on variola virus research: report of the thirteenth meeting report (World Health Organization, 2011), <https://apps.who.int/iris/handle/10665/70778>. Accessed 29 October 2021.
- [73] Xue L, Jing SL, Wang H (2022) Evaluating the impacts of non-pharmaceutical interventions on the transmission dynamics of COVID-19 in Canada based on mobile network. *PloS One* (in press).

Appendix A

$$\begin{aligned}
l_1 &= -(a_{11} + b_{12} + c_{13} + d_{13} + e_{12} + f_{13} + g_{13}), \\
l_2 &= -a_{12}b_{11} + c_{13}d_{13} + c_{13}e_{12} - c_{14}e_{11} + d_{13}e_{12} - d_{14}f_{11} + (c_{13} + d_{13} + e_{12})f_{13} \\
&\quad + g_{13}(c_{13} + d_{13} + e_{12} + f_{13}) + b_{12}(c_{13} + d_{13} + e_{12} + f_{13} + g_{13}) \\
&\quad + a_{11}(b_{12} + c_{13} + d_{13} + e_{12} + f_{13} + g_{13}), \\
l_3 &= a_{11}(-b_{12}(c_{13} + d_{13} + e_{12} + f_{13} + g_{13}) - c_{13}(d_{13} + e_{12} + f_{13} + g_{13}) + c_{14}e_{11} \\
&\quad - g_{13}(d_{13} + e_{12} + f_{13}) - d_{13}e_{12} - d_{13}f_{13} + d_{14}f_{11} - e_{12}f_{13}) \\
&\quad + a_{12}b_{11}(c_{13} + d_{13} + e_{12} + f_{13} + g_{13}) - g_{13}(b_{12}(c_{13} + d_{13} + e_{12} + f_{13}) \\
&\quad + c_{13}(d_{13} + e_{12} + f_{13}) - c_{14}e_{11} + f_{13}(d_{13} + e_{12}) + d_{13}e_{12} - d_{14}f_{11}) \\
&\quad - e_{11}(a_{13}c_{11} + b_{13}c_{12}) - c_{13}d_{13}e_{12} + c_{13}d_{14}f_{11} - c_{13}d_{13}f_{13} - c_{13}e_{12}f_{13} \\
&\quad - f_{11}(a_{14}d_{11} + b_{14}d_{12}) + d_{14}e_{12}f_{11} - d_{13}e_{12}f_{13} + c_{14}e_{11}(d_{13} + f_{13}) - d_{15}f_{11}g_{12} \\
&\quad - b_{12}(c_{13}(d_{13} + e_{12} + f_{13}) - c_{14}e_{11} + f_{13}(d_{13} + e_{12}) + d_{13}e_{12} - d_{14}f_{11})), \\
l_4 &= a_{13}e_{11}(c_{11}(b_{12} + d_{13}) - b_{11}c_{12}) + d_{13}(b_{12}c_{13}e_{12} - b_{12}c_{14}e_{11} + b_{13}c_{12}e_{11}) \\
&\quad + f_{11}(a_{14}(d_{11}(b_{12} + c_{13} + e_{12}) - b_{11}d_{12}) - d_{14}(e_{12}(b_{12} + c_{13}) + b_{12}c_{13} - c_{14}e_{11}) \\
&\quad + b_{14}d_{12}(c_{13} + e_{12})) - a_{12}(b_{11}(c_{13}(d_{13} + e_{12}) - c_{14}e_{11} + d_{13}e_{12} - d_{14}f_{11}) + b_{13}c_{11}e_{11} \\
&\quad + b_{14}d_{11}f_{11}) - e_{11}f_{12}(a_{14}c_{11} + b_{14}c_{12}) + b_{12}c_{13}d_{13}f_{13} + f_{13}(a_{13}c_{11}e_{11} \\
&\quad + e_{12}(d_{13}(b_{12} + c_{13}) + b_{12}c_{13}) - c_{14}e_{11}(b_{12} + d_{13}) + b_{13}c_{12}e_{11}) \\
&\quad - a_{12}b_{11}f_{13}(c_{13} + d_{13} + e_{12}) + d_{15}f_{11}g_{12}(b_{12} + c_{13} + e_{12}) - a_{12}b_{11}g_{13}(c_{13} \\
&\quad + d_{13} + e_{12} + f_{13}) + g_{13}(a_{13}c_{11}e_{11} + a_{14}d_{11}f_{11} + b_{12}(c_{13}(d_{13} + e_{12} + f_{13}) \\
&\quad - c_{14}e_{11} + f_{13}(d_{13} + e_{12}) + d_{13}e_{12} - d_{14}f_{11}) + b_{13}c_{12}e_{11} + b_{14}d_{12}f_{11} \\
&\quad + c_{13}d_{13}e_{12} + c_{13}d_{13}f_{13} - c_{13}d_{14}f_{11} + c_{13}e_{12}f_{13} - c_{14}e_{11}(d_{13} + f_{13}) \\
&\quad + d_{13}e_{12}f_{13} - d_{14}e_{12}f_{11}) + a_{11}(b_{13}c_{12}e_{11} + b_{14}d_{12}f_{11} + c_{13}(f_{13}(d_{13} + e_{12}) \\
&\quad + d_{13}e_{12} - d_{14}f_{11}) + d_{13}e_{12}f_{13} - d_{14}e_{12}f_{11} + d_{15}f_{11}g_{12}) + a_{11}(b_{12}(c_{13}(d_{13} \\
&\quad + e_{12} + f_{13} + g_{13}) - c_{14}e_{11} + d_{13}(e_{12} + f_{13} + g_{13}) - d_{14}f_{11} + g_{13}(e_{12} + f_{13}) \\
&\quad + e_{12}f_{13}) + g_{13}(c_{13}(d_{13} + e_{12} + f_{13}) + d_{13}(e_{12} + f_{13}) - d_{14}f_{11} + e_{12}f_{13}) \\
&\quad - c_{14}e_{11}(d_{13} + f_{13} + g_{13})),
\end{aligned}$$

$$\begin{aligned}
l_5 = & a_{12}(b_{11}(g_{13}(c_{13}(d_{13} + e_{12} + f_{13}) + f_{13}(d_{13} + e_{12}) + d_{13}e_{12} - d_{14}f_{11}) + c_{13}d_{13}e_{12} \\
& + c_{13}d_{13}f_{13} - c_{13}d_{14}f_{11} + c_{13}e_{12}f_{13} - c_{14}e_{11}(d_{13} + f_{13} + g_{13}) + d_{13}e_{12}f_{13} \\
& - d_{14}e_{12}f_{11} + d_{15}f_{11}g_{12}) + b_{13}c_{11}e_{11}(d_{13} + f_{13} + g_{13}) + b_{14}(d_{11}f_{11}(c_{13} + e_{12} + g_{13}) \\
& - c_{11}e_{11}f_{12})) - a_{13}e_{11}(-b_{11}c_{12}(d_{13} + f_{13} + g_{13}) + b_{12}c_{11}(d_{13} + f_{13} + g_{13}) \\
& + c_{11}(g_{13}(d_{13} + f_{13}) + d_{13}f_{13} - d_{14}f_{11})) - g_{13}(f_{11}(a_{14}(d_{11}(c_{13} + e_{12}) - b_{11}d_{12}) \\
& + b_{14}d_{12}(c_{13} + e_{12}) - c_{13}d_{14}e_{12} + c_{14}d_{14}e_{11}) - b_{12}(-a_{14}d_{11}f_{11} - c_{13}d_{13}e_{12} \\
& + d_{14}f_{11}(c_{13} + e_{12}) + c_{14}d_{13}e_{11}) - e_{11}f_{12}(a_{14}c_{11} + b_{14}c_{12}) + b_{13}c_{12}d_{13}e_{11} \\
& + f_{13}(b_{12}(c_{13}(d_{13} + e_{12}) - c_{14}e_{11} + d_{13}e_{12}) + b_{13}c_{12}e_{11} + c_{13}d_{13}e_{12} - c_{14}d_{13}e_{11}) \\
& + a_{11}(b_{12}(c_{13}(d_{13} + e_{12} + f_{13}) - c_{14}e_{11} + f_{13}(d_{13} + e_{12}) + d_{13}e_{12} - d_{14}f_{11}) \\
& + b_{13}c_{12}e_{11} + b_{14}d_{12}f_{11} + c_{13}d_{13}e_{12} + c_{13}d_{13}f_{13} - c_{13}d_{14}f_{11} + c_{13}e_{12}f_{13} \\
& - c_{14}e_{11}(d_{13} + f_{13}) + d_{13}e_{12}f_{13} - d_{14}e_{12}f_{11})) + a_{14}e_{11}f_{12}(c_{11}(b_{12} + d_{13}) - b_{11}c_{12}) \\
& + a_{14}f_{11}(b_{11}d_{12}(c_{13} + e_{12}) - b_{12}d_{11}(c_{13} + e_{12}) - c_{13}d_{11}e_{12} + c_{14}d_{11}e_{11}) \\
& - d_{15}f_{11}g_{12}(b_{12}(c_{13} + e_{12}) + c_{13}e_{12} - c_{14}e_{11}) + b_{14}c_{12}d_{13}e_{11}f_{12} + f_{11}(d_{14}(b_{12}c_{13}e_{12} \\
& - b_{12}c_{14}e_{11} + b_{13}c_{12}e_{11}) + b_{14}d_{12}(c_{14}e_{11} - c_{13}e_{12})) - d_{13}f_{13}(b_{12}c_{13}e_{12} - b_{12}c_{14}e_{11} \\
& + b_{13}c_{12}e_{11}) + a_{11}(-f_{13}(b_{12}(c_{13}(d_{13} + e_{12}) - c_{14}e_{11} + d_{13}e_{12}) + b_{13}c_{12}e_{11} + c_{13}d_{13}e_{12} \\
& - c_{14}d_{13}e_{11}) - b_{12}c_{13}d_{13}e_{12} + b_{12}c_{13}d_{14}f_{11} - d_{15}f_{11}g_{12}(b_{12} + c_{13} + e_{12}) + b_{12}c_{14}d_{13}e_{11} \\
& + b_{12}d_{14}e_{12}f_{11} - b_{13}c_{12}d_{13}e_{11} + b_{14}c_{12}e_{11}f_{12} - b_{14}c_{13}d_{12}f_{11} - b_{14}d_{12}e_{12}f_{11} \\
& + c_{13}d_{14}e_{12}f_{11} - c_{14}d_{14}e_{11}f_{11}),
\end{aligned}$$

$$\begin{aligned}
l_6 = & a_{13}e_{11}(-g_{13}(b_{11}c_{12}(d_{13} + f_{13}) - c_{11}d_{13}f_{13} + c_{11}d_{14}f_{11}) - b_{11}c_{12}d_{13}f_{13} + b_{11}c_{12}d_{14}f_{11} \\
& + b_{12}c_{11}(g_{13}(d_{13} + f_{13}) + d_{13}f_{13} - d_{14}f_{11}) + b_{14}f_{11}(c_{11}d_{12} - c_{12}d_{11}) + c_{11}d_{15}f_{11}g_{12}) \\
& + a_{14}(b_{11}c_{12}d_{13}e_{11}f_{12} - b_{11}c_{13}d_{12}e_{12}f_{11} + b_{11}c_{14}d_{12}e_{11}f_{11} - b_{12}(c_{11}d_{13}e_{11}f_{12} \\
& - c_{13}d_{11}e_{12}f_{11} + c_{14}d_{11}e_{11}f_{11}) + b_{13}e_{11}f_{11}(c_{12}d_{11} - c_{11}d_{12}) - c_{11}d_{15}e_{11}f_{11}g_{11} \\
& + g_{13}(f_{11}(-b_{11}d_{12}(c_{13} + e_{12}) + b_{12}d_{11}(c_{13} + e_{12}) + c_{13}d_{11}e_{12} - c_{14}d_{11}e_{11}) \\
& - e_{11}f_{12}(c_{11}(b_{12} + d_{13}) - b_{11}c_{12}))) - g_{13}(a_{11}(b_{12}d_{13}(c_{14}e_{11} - c_{13}e_{12}) \\
& + b_{12}d_{14}f_{11}(c_{13} + e_{12}) - b_{13}c_{12}d_{13}e_{11} + b_{14}c_{12}e_{11}f_{12} - f_{11}(b_{14}d_{12}(c_{13} + e_{12}) \\
& - c_{13}d_{14}e_{12} + c_{14}d_{14}e_{11})) + d_{14}f_{11}(b_{12}c_{13}e_{12} - b_{12}c_{14}e_{11} + b_{13}c_{12}e_{11}) \\
& + b_{14}(c_{12}d_{13}e_{11}f_{12} - c_{13}d_{12}e_{12}f_{11} + c_{14}d_{12}e_{11}f_{11}) + a_{12}(b_{11}(c_{13}(f_{13}(d_{13} + e_{12}) \\
& + d_{13}e_{12} - d_{14}f_{11}) - c_{14}e_{11}(d_{13} + f_{13}) + d_{13}e_{12}f_{13} - d_{14}e_{12}f_{11}) + b_{13}c_{11}e_{11}(d_{13} + f_{13}) \\
& - b_{14}c_{11}e_{11}f_{12} + b_{14}d_{11}f_{11}(c_{13} + e_{12})) - f_{13}(a_{11}(b_{12}(e_{12}(c_{13} + d_{13}) + c_{13}d_{13} - c_{14}e_{11}) \\
& + b_{13}c_{12}e_{11} + c_{13}d_{13}e_{12} - c_{14}d_{13}e_{11}) + d_{13}(b_{12}c_{13}e_{12} - b_{12}c_{14}e_{11} + b_{13}c_{12}e_{11}))) \\
& + a_{11}(-(d_{14}f_{11} - d_{13}f_{13})(b_{12}c_{13}e_{12} - b_{12}c_{14}e_{11} + b_{13}c_{12}e_{11}) + d_{15}f_{11}g_{12}(e_{12}(b_{12} + c_{13}) \\
& + b_{12}c_{13} - c_{14}e_{11}) - b_{14}(c_{12}d_{13}e_{11}f_{12} - c_{13}d_{12}e_{12}f_{11} + c_{14}d_{12}e_{11}f_{11})) + a_{12}((d_{14}f_{11} \\
& - d_{13}f_{13})(b_{11}c_{13}e_{12} - b_{11}c_{14}e_{11} + b_{13}c_{11}e_{11}) - b_{11}d_{15}f_{11}g_{12}(c_{13} + e_{12}) \\
& + b_{14}(c_{11}d_{13}e_{11}f_{12} - c_{13}d_{11}e_{12}f_{11} + c_{14}d_{11}e_{11}f_{11})) + d_{15}f_{11}(g_{12}(b_{12}c_{13}e_{12} - b_{12}c_{14}e_{11} \\
& + b_{13}c_{12}e_{11}) - b_{14}c_{12}e_{11}g_{11}),
\end{aligned}$$

$$\begin{aligned}
l_7 = & a_{14}d_{15}e_{11}f_{11}g_{11}(b_{12}c_{11} - b_{11}c_{12}) + g_{13}(a_{11}((d_{14}f_{11} - d_{13}f_{13})(b_{12}c_{13}e_{12} - b_{12}c_{14}e_{11} \\
& + b_{13}c_{12}e_{11}) + b_{14}(c_{12}d_{13}e_{11}f_{12} - c_{13}d_{12}e_{12}f_{11} + c_{14}d_{12}e_{11}f_{11})) - a_{12}(d_{14}f_{11}(b_{11}c_{13}e_{12} \\
& - b_{11}c_{14}e_{11} + b_{13}c_{11}e_{11}) + b_{14}(c_{11}d_{13}e_{11}f_{12} - c_{13}d_{11}e_{12}f_{11} + c_{14}d_{11}e_{11}f_{11})) \\
& + a_{12}d_{13}f_{13}(b_{11}c_{13}e_{12} - b_{11}c_{14}e_{11} + b_{13}c_{11}e_{11}) + a_{13}e_{11}((b_{12}c_{11} - b_{11}c_{12})(d_{14}f_{11} \\
& - d_{13}f_{13}) + b_{14}f_{11}(c_{12}d_{11} - c_{11}d_{12}))) + d_{15}f_{11}(g_{12}(e_{11}(a_{11}b_{12}c_{14} - a_{11}b_{13}c_{12} \\
& - a_{12}b_{11}c_{14} + a_{12}b_{13}c_{11} + a_{13}b_{11}c_{12} - a_{13}b_{12}c_{11}) + c_{13}e_{12}(a_{12}b_{11} - a_{11}b_{12})) \\
& + b_{14}e_{11}g_{11}(a_{11}c_{12} - a_{12}c_{11})) + a_{14}g_{13}(d_{13}e_{11}f_{12}(b_{12}c_{11} - b_{11}c_{12}) + f_{11}(b_{12}d_{11} \\
& - b_{11}d_{12})(c_{14}e_{11} - c_{13}e_{12}) + b_{13}e_{11}f_{11}(c_{11}d_{12} - c_{12}d_{11})).
\end{aligned}$$

$$\begin{aligned}
a_{11} = & -\beta_1 I_1^* - \beta_2 I_2^* - (\mu + p), \quad a_{12} = \gamma, \quad a_{13} = -\beta_1 S^*, \quad a_{14} = -\beta_2 S^*, \\
b_{11} = & p, \quad b_{12} = -\delta_1 \beta_1 I_1^* - \delta_2 \beta_2 I_2^* - (\mu + \gamma), \quad b_{13} = -\delta_1 \beta_1 V^*, \\
b_{14} = & -\delta_2 \beta_2 V^*, \quad c_{11} = \beta_1 I_1^*, \quad c_{12} = \delta_1 \beta_1 I_1^*, \quad c_{13} = -(a_1 + \mu), \\
c_{14} = & \beta_1 (S^* + \delta_1 V^*), \quad d_{11} = \beta_2 I_2^*, \quad d_{12} = \delta_2 \beta_2 I_2^*, \quad d_{13} = -(a_2 + \mu), \\
d_{14} = & \beta_2 (S^* + \delta_2 V^*) + \delta_3 \beta_2 R_1^*, \quad d_{15} = \delta_3 \beta_2 I_2^*, \quad e_{11} = a_1, \\
e_{12} = & -(\alpha_2 + \mu + d_1 + \nu_1), \quad f_{11} = a_2, \quad f_{12} = \nu_1, \quad f_{13} = -(\alpha_2 + \mu + d_2), \\
g_{11} = & \alpha_1, \quad g_{12} = -\delta_3 \beta_2 R_1^*, \quad g_{13} = -(\delta_3 \beta_2 I_2^* + \mu).
\end{aligned}$$